INVITATION PROGRAMME
Call for Abstracts / Scientific Programme

WFSBP Congress 2017

13th World Congress of Biological Psychiatry

18 – 22 June 2017
Copenhagen, Denmark
Bella Center Copenhagen

www.wfsbp-congress.org

Organised by: World Federation of Societies of Biological Psychiatry

Hosted by the Danish Society of Biological Psychiatry
# Table of Contents

Page

3  Invitation to the 13th World Congress of Biological Psychiatry

4  About WFSBP

5  About the WFSBP Congress 2017
   - Congress Administration
   - WFSBP Executive Committee
   - International Scientific Programme Committee
   - Honorary Committee (HC)
   - National Presidents
   - Chairs of the Local Organising Committee (LOC)
   - Congress Ambassadors

Congress Programme

7  Colour Legend

8  Preliminary Scientific Programme Schedule

13  Preliminary Scientific Programme

39  Topics

41  Call for Abstracts for Free Communications and Posters

42  Format Descriptions of the Scientific Sessions

43  WFSBP Awards

44  Congress Information

45  General Information

---

**WFSBP GLOBAL HEADQUARTERS**
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49 – 40 – 670 882 90
Fax: +49 – 40 – 670 328 82 91
Email: info@wfsbp.org
[www.wfsbp-congress.org](http://www.wfsbp-congress.org)

**CONGRESS VENUE**
Bella Center Copenhagen
Center Boulevard 5
2300 Copenhagen S, Denmark
[www.bellacentercopenhagen.dk](http://www.bellacentercopenhagen.dk)

**CONGRESS AND EXHIBITION OFFICE**
CPO Hanser Service
Phone: +49 – 30 – 300 669-0
Email: wfsbp2017@cpo-hanser.de
Dear Colleagues,

It is both an honor and a privilege to welcome all of you to the 13th World Congress of Biological Psychiatry in Copenhagen, 18–22 June 2017, which will be an excellent setting to discuss the current progress in molecular biology, the development of novel drugs based upon new concepts, and the advances in modern neuroscience that will change our approach to psychiatric disorders and our attitudes towards mental health care. It is the time for biological psychiatry to be developed into the new stage where biopsychosocio-spiritual aspects are integrated for the betterment of patients and families with mental and psychiatric disorders. The field of biological psychiatry is expanding by the development of bioinformatics (genomics, transcriptomics, proteomics) identifying importance of glycome, lipidome, metabolome, and deseaseome, and brain activity mapping methodology.

Looking back a few examples of previous world congress of biological psychiatry in Paris (2009), Prague (2011), Kyoto (2013), and Athens (2015), it is remarkable to have witnessed significant contribution of biological psychiatry research into the diagnosis, treatment, care, and even prevention of psychiatric and mental disorders.

The field of biological psychiatry is rapidly developing, reaching the new stage of clinical application. Genetic engineering, iPS cells, brain mapping, and other new technologies have been integrated into the translational research in the field. Modified electroconvulsive therapy (mECT), repetitive trans-cranial stimulation (rTMS), near-infrared spectroscopy (NIRS), and decoded neurofeedback (DecNeF) are examples of recent application in biological psychiatry. Considering the impact of most CNS disorders, biological psychiatry is expected to fill in the unmet need for CNS drugs including new generation antipsychotics, anti-depressants, anti-epileptics, anxiolytics, and sleep inducers, and others. Biological psychiatry is the field where academia and industry should proceed together aiming for the developing of new methods of diagnosis and treatment of CNS disorders.

We are confident that the 13th World Congress of Biological Psychiatry in Copenhagen will be the superb setting for presentation and discussion of recent findings in biological psychiatry. To this end, 5 Lectures, 3 Debates, 12 Task Force Symposia/Workshops and 83 independent Symposia/Workshops are already forming the core scientific programme; all of them on very interesting topics to be presented by prominent researchers-scientists in their respective fields.

We trust that the breadth of topics our congress is tackling, will encourage many more colleagues around the world to submit their recent findings, through our Free Communication and Poster presentation sessions. For more information regarding relevant deadlines, please visit our congress website.

We are looking forward to meeting you in Copenhagen and interacting with you both socially and professionally.

With our best wishes

Prof. Masatoshi Takeda
Congress President

Prof. Constantin R. Soldatos
Chair of the International Scientific Programme Committee

Prof. Gregers Wegener
Chair of the Local Organising Committee
About WFSBP

Founded in 1974 in Buenos Aires, Argentina, the World Federation of Societies of Biological Psychiatry is a non-profit world wide organization composed of 63 National Societies of Biological Psychiatry and Individual Members representing professionals from over 70 countries.

With this multitude of countries represented in its worldwide community, the World Federation has built an international network of over 4,500 opinion leaders, the majority of which are key opinion-leaders in the practice of Biological Psychiatry.

WFSBP members by continent

The principle objectives of WFSBP are:
- To foster and encourage scientific research and advancement in the field of Biological Psychiatry
- To improve the quality of training spanning all the biological psychiatry sciences
- To promote education and achieve the highest level of knowledge and understanding within the field
- To provide information and guidance to all institutions, societies or individuals with an interest in biological psychiatry
- To establish, build, and maintain solid collaboration with international and national organisations related to biological psychiatry

Educational activities, regional, international and world congresses, the interactive website www.wfsbp.org, and The World Journal of Biological Psychiatry build the World Federation’s portfolio and insure its worldwide influence. The development of worldwide treatment guidelines is one of WFSBP’s main areas of international leadership.

Year after year, more and more professionals choose to join the World Federation’s Biological Psychiatry arena and enjoy its exclusive educational and networking opportunities. In the coming years WFSBP is looking forward to welcoming over 15 new eminent member societies from different parts of the world.

WFSBP members by field of activity:

As of December 2015
CONGRESS ADMINISTRATION
The 13th World Congress of Biological Psychiatry will be organised by the World Federation of Societies of Biological Psychiatry (WFSBP)

WFSBP EXECUTIVE COMMITTEE
President (2015 – 2019)
Masatoshi Takeda, Japan

Vice President (2013 – 2017)
Tudor Udristoiu, Romania

Past President (2015 – 2017)
Constantin R. Soldatos, Greece

Secretary (2013 – 2017)
Lakshmi N. Yatham, Canada

Treasurer (2013 – 2017)
Martin Hatzinger, Switzerland

Vice Secretary (2013 – 2017)
Ladislav Hosak, Czech Republic

Vice Treasurer (2013 – 2017)
Victoria Valdez, Ecuador

INTERNATIONAL SCIENTIFIC PROGRAMME COMMITTEE (ISPC)
Chair
Constantin R. Soldatos, Greece

Members of ISPC
G. Alexopoulos, USA*
C. A. Altamura, Italy*
C. Arango, Spain
E. Baca Garcia, Spain
M. Bauer, Germany*
E. Belfort, Venezuela
A. Benyamina, France
M. Berk, Australia*
J. Bobes, Spain
A. Bozkurt, Cyprus
N. Boutros, USA
C. L. Bowdlen, USA
P. Boyer, France
J. Bradford, Canada
P. Brambilla, Italy
M. Bras, Croatia
M. S. Buchsbaum, USA
A. Burns, UK
R. Castilla-Puentes, USA*
D. Castle, Australia*
E. Ceskova, Czech Republic*
M. Cetkovich-Bakmas, Argentina
Y. Hwa Chou, Taiwan*
H. Correa, Brazil*
P. Cosyns, Belgium
P. Courtet, France*
B. Dean, Australia*
J. de Buitelaar, The Netherlands
M. Dierick, Belgium
B. Dubois, France
K. Fountoulakis, Greece*
S. Frangou, UK
W. Gaebel, Germany
F. D. Garcia, Brazil*
W. F.Gattaz, Brazil
P. Gejman, USA
A. Germanavicious, Lithuania
M. George, USA*
A. H. Glassman, USA
B. Glenthoj, Denmark
G. M. Goodwin, UK
D. Gorelick, USA
P. Gorwood, France*
A. Grace, USA*
H. Grunze, UK*
G. Hajak, Germany
A. Halaris, USA*
A. Hasan, Germany
S. Heckers, USA
C. Hiemke, Germany
E. Hollander, USA
E. Holsboer-Trachsler, Switzerland*
W. G. Honer, Canada
J. Horacek, Czech Republic
A. Jablensky, Australia
R. Kahn, The Netherlands
J. Kane, USA
S. Kanba, Japan*
T. Kato, Japan
C. Katona, UK
W. Kaye, USA
J. Kennedy, Canada*
L. Konopka, USA
H. R. Kranzler, USA*
C. Krieg, Germany
T. Kudo, Japan
J. Soo Kwon, Korea
S. Lamy, France
R. Lanzenberger, Austria*
V. Larach, Chile
M. Leboyer, France
M.S. Lee, Korea*
M. Lejoyeux, France
B. Leonard, Ireland*
Y. Levkovitz, Israel
A. Lopez Mato, Argentina*
C. Lyketsos, USA

* Special correspondents of ISC Core Group
About the WFSBP Congress 2017

R. McCarley, USA
P. Mc Gorry, Australia
P. Mc Guire, UK
M. Maes, Belgium*
A. Malafosse, Switzerland
J.-L. Martinot, France
V. Matei, Romania*
H. Mayberg, USA
H. Y. Meltzer, USA
A. Meyer-Lindenberg, Germany
A. Kant Mital, India
E. Mohan Das, India
N. Müller, Germany
T. Murai, Japan*
Z. Nahas, Lebanon
D. Nutt, UK
J. Ospina-Duque, Colombia*
N. Ozaki, Japan
C. Pantelis, Australia*
G. Papadimitriou, Greece
T. Paparrigopoulos, Greece*
G. Parker, Australia
L. Pezewas, Austria
O. Pogarell, Germany
S. G. Potkin, USA
R. Post, USA*
M. Rapaport, USA
M.S. Reddy, India*
E. Richelson, USA
P. Riederer, Germany
D. Rujescu, Germany
R. Rupprecht, Germany
J. Rybakowski, Poland
H. Sackeim, USA
T. Saito, Japan
P. Salgado Pineda, Spain
M. Sarchiapone, Italy
T. Schlaepfer, Germany*
A. Schmitt, Germany
L. Schneider, USA
C. Schulz, USA
T. G. Schulze, Germany*
S. Seedat, South Africa*
E. Seifritz, Switzerland
A. Serretti, Italy*
E. Serfaty, Argentina
W. W. Shen, Taiwan
L. Siever, USA
D. St. Clair, UK
N. Stefanis, Greece*
J. Steiner, Germany
T. Suhara, Japan
M. Taleb, France/Algeria
T. Taneli, USA
J. Tellez-Vargas, Colombia
J. Treasure, UK
N. A. Uranova, Russia
P. Udomratn, Thailand*
I. Udrostitoiu, Romania*
W. van den Brink, The Netherlands*
J. van Os, The Netherlands
D. Velakoulis, Australia*
N. Venizelos, Sweden*
E. Vieta, Spain*
J. Waddington, Ireland
A. Weinstein Israel
P. Whybrow, USA
X. Yu, China
M. Zanarini, USA
Y. Zervas, Greece*
J. Zohar, Israel

HONORARY COMMITTEE (HC)
Jules Angst, Switzerland
Jose Luis Ayuso, Spain
Jorge Cipriani-Ollivier, Argentina
Jorge Alberto Costa e Silva, Brazil
Tetsuo Fukuda, Japan
Gerardo Heinze, Mexico
Carlos Roberto Hojaij, Brazil
Florian Holsboer, Germany
Siegfried Kasper, Austria
Jeffrey Lieberman, USA
Julien Mendlewicz, Belgium
Hans-Jürgen Möller, Germany
Robin Murray, UK
Ahmed Okasha, Egypt
Mitsuomi Sato, Japan
Norman Sartorius, Switzerland
Göran Sedvall, Sweden
Costas Stefanis, Greece
Florence Thibaut, France
Michael Trimble, UK

NATIONAL PRESIDENTS
A. Corrales, Argentina
A. Boyajyan, Armenia
C. Geretsegger, Austria
S. Claes, Belgium
N. D. Noya-Tapia, Bolivia
A. Kucukalic, Bosnia-Herzegovina
A. Marcelino, Brazil
O. Atanasova Mikova-Demireva, Bulgaria
R. W. Lam, Canada
E. Olea, Chile
C. Gutierrez, Columbia
R. Castro, Costa Rica
M. Jakovljevic, Croatia
L. Hosak, Czech Republic
G. Wegener, Denmark
F. Solis de Mendez, Dominican Republic
M. Meneses-Guevara, Ecuador
A. Okasha, Egypt
M. Meija Pena, El Salvador
J. Harro, Estonia
P. Courtet, France
S. Hertzberg, Germany
C. R. Soldatos, Greece
H. Soto Chavez, Guatemala
M. Aguilar Lopez, Honduras
S.-W. Tang, Hong Kong
C. Banki, Hungary
R. Nagpal, India
A. J. Tanra, Indonesia
D. Gothelf, Israel
M. Maj, Italy
T. Nishikawa, Japan
M. Assimov, Kazakhstan
C. Uk Lee, Korea
B. Kupca, Latvia
C. Baddoura, Lebanon
J. Neveranskas, Lithuania
B. Stefanovski, Macedonia
S. Krishnaswamy, Malaysia
D. Moussaoui, Morocco
G. Villanueva Colin, Mexico
H. Lovdahl, Norway
M. Amin, Pakistan
G. Da Costa, Panama

* Special correspondents of ISC Core Group
About the WFSBP Congress 2017 / Colour Legend

L. Villalba, Paraguay
E. Galli, Peru
A. Wichniak, Poland
J. Relvas, Portugal
T. Udristoiu, Romania
S. Mosolov, Russia
N. Maric Bojovic, Serbia
L. Vavrusova, Slovakia
S. Seedat, South Africa
M. Bernardo, Spain
M. Ramklin, Sweden
M. Hatzinger, Switzerland
Ch.-Y. Liu, Taiwan
P. Udomratn, Thailand
B. Taneli, Turkey
A. V. Kalueff, Ukraine
G. Bouza, Uruguay
J. Ibáñez-Domínguez, Venezuela

Members of LOC
Kjeld Andersen, Denmark
Ole A. Andreassen, Norway
Lone Baandrup, Denmark
Per Bech, Denmark
Nils Bilenberg, Denmark
Bjørn Ebdrup, Denmark
Jesper Ekelund, Finland
Anders Fink-Jensen, Denmark
Birte Glenthøj, Denmark
Simon Glerup, Denmark
Jaanus Harro, Estonia
Torsten Bjørn Jacobsen, Denmark
Martin Balslev Jørgensen, Denmark
Olli Kampman, Finland
Lars Kessing, Denmark
Gitte Moos Knudsen, Denmark
Rasmus Licht, Denmark
Pall Mathiasson, Iceland
Tanja Michel, Denmark
Thomas Middelboe, Denmark
Ole Mors, Denmark
Merete Nordentoft, Denmark
Kerstin Plessen, Denmark
Andreas Reif, Germany
Dan Rujescu, Germany
Bo Söderpalm, Sweden
Per Hove Thomsen, Denmark
Jari Tiihonen, Sweden
Anders Tingström, Sweden
Poul Videbech, Denmark
Thomas Werge, Denmark

CONGRESS AMBASSADORS
Carlo Altamura, Italy
Ajit Avasthi, India
Charles Baddoura, Lebanon
Robert Belmaker, Israel
Enrique Galli, Peru
Peter Gaszner, Hungary
Bai Han, China
Gerhard Heinze, Mexico
Nick Kates, Canada
Donatella Marazziti, Italy
Giorgio Racagni, Italy
M.S. Reddy, India
Pedro Ruiz, USA
Janusz Rybakowski, Poland
Dan Stein, South Africa
Andi J. Tanra, Indonesia
Si Tian-Mei, China
Eduard Vieta, Spain
Shigeto Yamawaki, Japan
Yukio Yoneda, Japan
Allan Young, UK

CHAIRS OF THE LOCAL ORGANISING COMMITTEE (LOC)

Chair
Gregers Wegener, Denmark

Deputy Chairs
Ida Hageman, Denmark
Søren Dinesen Østergaard, Denmark

COLOUR CODES OF SESSIONS (PRELIMINARY SCIENTIFIC PROGRAMME, PAGES 8 – 38)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>OP</td>
<td>Opening Lecture</td>
</tr>
<tr>
<td>PL</td>
<td>Plenary Lectures</td>
</tr>
<tr>
<td>D</td>
<td>Debates</td>
</tr>
<tr>
<td>TFS</td>
<td>Task Force Symposia</td>
</tr>
<tr>
<td>TFW</td>
<td>Task Force Workshops</td>
</tr>
<tr>
<td>S</td>
<td>Symposia</td>
</tr>
<tr>
<td>WS</td>
<td>Workshops</td>
</tr>
<tr>
<td>FC</td>
<td>Free Communications</td>
</tr>
<tr>
<td>SA</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td>8:30</td>
<td>S-01</td>
</tr>
<tr>
<td>8:30</td>
<td>S-02</td>
</tr>
<tr>
<td>8:30</td>
<td>S-03</td>
</tr>
<tr>
<td>8:30</td>
<td>WS-01</td>
</tr>
<tr>
<td>9:00</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>S-04</td>
</tr>
<tr>
<td>9:30</td>
<td>S-05</td>
</tr>
<tr>
<td>9:30</td>
<td>S-06</td>
</tr>
<tr>
<td>9:30</td>
<td>WS-02</td>
</tr>
<tr>
<td>10:00</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>S-07</td>
</tr>
<tr>
<td>10:30</td>
<td>S-08</td>
</tr>
<tr>
<td>10:30</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>S-09</td>
</tr>
<tr>
<td>13:00</td>
<td>S-10</td>
</tr>
<tr>
<td>13:00</td>
<td>S-11</td>
</tr>
<tr>
<td>13:00</td>
<td>S-12</td>
</tr>
<tr>
<td>14:00</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>S-13</td>
</tr>
<tr>
<td>17:00</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>8:30</td>
<td>S-14 Problematic sexual behaviors: Diagnostic, categorical, epidemiological, imaging, psychopathological and treatment considerations</td>
</tr>
<tr>
<td>9:00</td>
<td>S-15 Posttraumatic Stress Disorder (PTSD) and gender</td>
</tr>
<tr>
<td>9:30</td>
<td>S-16 The elephant in the room: The role of glial cells in psychiatric disorders</td>
</tr>
<tr>
<td>10:00</td>
<td>S-17 Psychosis is disrespectful to diagnostic boundaries: Nosological and pathobiological implications of psychoses beyond ...</td>
</tr>
<tr>
<td>11:00</td>
<td>S-18 Epigenetic modification, effect of early life stress, and signaling mechanisms in suicide</td>
</tr>
<tr>
<td>11:30</td>
<td>S-19 Psychodetics: Mechanisms and applications in psychiatry</td>
</tr>
<tr>
<td>12:00</td>
<td>S-20 Affective and psychotic psychopathology from pregnancy to early adulthood: The dynamic developmental interplay ...</td>
</tr>
<tr>
<td>10:30</td>
<td>PL-01 Drug discovery in neuroscience: Promises, barriers and opportunities</td>
</tr>
<tr>
<td>12:30</td>
<td>D-01 Antidepressants are effective for treating acute bipolar depression</td>
</tr>
<tr>
<td>12:30</td>
<td>TFS-01 Therapeutic drug monitoring, pharmacogenetics and brain imaging methods as tools for optimizing pharmacotherapy in psychiatry</td>
</tr>
<tr>
<td>12:30</td>
<td>S-21 Measurement-based psychiatry: Toward rating scale-based assessments in the real world</td>
</tr>
<tr>
<td>12:30</td>
<td>S-22 Dissecting the shared and non-shared biological features in schizophrenia and autism spectrum disorder</td>
</tr>
<tr>
<td>13:00</td>
<td>S-23 Combining cognitive remediation with brain imaging techniques: Evidence for neural changes or neuroplasticity?</td>
</tr>
<tr>
<td>13:00</td>
<td>WS-03 Current status of electroconvulsive therapy in the treatment of major psychiatric disorders</td>
</tr>
<tr>
<td>13:00</td>
<td>S-24 Serotonin and anxiety disorders: Recent evidences from neuroimaging studies</td>
</tr>
<tr>
<td>14:00</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td>14:30</td>
<td>S-25 tDCS: From research to clinical practice</td>
</tr>
<tr>
<td>14:30</td>
<td>TFS-02 Post-mortem findings across psychiatric disorders and their association with cognitive symptoms</td>
</tr>
<tr>
<td>14:30</td>
<td>TFW-01 Workshop of the WFSBP Task Force on Genetics: Focus on pharmaco-genomics</td>
</tr>
<tr>
<td>14:30</td>
<td>S-26 Into novel drugs for depression</td>
</tr>
<tr>
<td>14:30</td>
<td>S-27 Beyond unitary models of psychosis: Confronting complex etiology and dimensionality</td>
</tr>
<tr>
<td>14:30</td>
<td>WS-04 Rethinking depression in the Century XXI: Where are we now in biological psychiatry?</td>
</tr>
<tr>
<td>14:30</td>
<td>S-28 Wake and sleep electroencephalogram provide biomarkers of depression</td>
</tr>
<tr>
<td>15:00</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td>15:30</td>
<td>S-29 Autism spectrum disorders in adults – from the clinical phenotype to the underlying neurobiology – novel techincs such ...</td>
</tr>
<tr>
<td>15:30</td>
<td>TFS-03 Update biomarkers in psychiatry</td>
</tr>
<tr>
<td>16:00</td>
<td>TFS-03 Update biomarkers in psychiatry</td>
</tr>
<tr>
<td>16:30</td>
<td>Technical Exhibition</td>
</tr>
<tr>
<td>17:00</td>
<td>Registration Counter</td>
</tr>
<tr>
<td>17:30</td>
<td>Free Communications</td>
</tr>
<tr>
<td>18:00</td>
<td>Free Communications</td>
</tr>
<tr>
<td>18:30</td>
<td>Free Communications</td>
</tr>
</tbody>
</table>
### Preliminary Scientific Programme Schedule / Tuesday, 20 June 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>S-30 Recent insights in schizophrenia physiopathology and treatments</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>S-31 Duration of untreated psychosis: From neuromaging to clinical trials</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>S-32 New perspectives on transcranial magnetic stimulation in psychiatric disorders</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>S-33 Epigenetic biomarkers for the diagnosis of mood disorders</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>S-34 Sex hormones and their wide-ranging effects on psychopathology</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>WS-05 Gesture as window to psychosis pathobiology: From aberrant body experience to social interaction</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>S-35 New insights into the neurobiology and treatment aspects of obsessive compulsive disorder comorbid with schizophrenia and bipolar depression</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>Free Communications</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Plenary Lecture</td>
<td>PL-02 Novel treatments in mood disorders: Molecular mechanisms and clinical applications</td>
</tr>
<tr>
<td>10:00</td>
<td>D-02 The Research Domain Criteria (RDoC) can create a new kind of taxonomy holding greater promise compared to the traditional taxonomy</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>TFS-04 Sleep in depression and cognition – from research to clinical practice</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>S-36 The role of the nucleus accumbens in psychiatry</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>S-37 Neurobiologic imaging studies of mood disorders, neuromarkers, and antidepressant action with positron emission tomography</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>S-38 Treatment resistant schizophrenia: Definitions, psychobiology and clinical treatment</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>WS-06 Neurobiology of suicidal behaviour</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Free Communications</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Satellite Symposia</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>WS-07 Merging evidence and clinical practice in management of depression: The CANMAT experience</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>TFS-05 Biomarkers for schizophrenia: from molecules to brain function. A consensus of the WFSBP Task Force on biological markers</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>TFW-02 WFSBP Consensus on the management of agitation in psychiatry</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>S-39 Current research on the use of cannabinoids</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>S-40 Alzheimer’s Disease (AD) pathophysiology, prevention and treatment strategies: Where we stand and where we go?</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>WS-08 Functional neuroanatomy of hallucinations</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>S-41 Electroconvulsive therapy for depression – optimising treatment and maintaining recovery</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>Free Communications</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>Satellite Symposia</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>S-42 Neuroepigenetic approaches to assess disease risk, mechanism and treatment</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>TFS-06 Electroconvulsive therapy: beyond depression</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>Registration Counter 08:00–18:30</td>
<td>Poster Exhibition 09:00–17:00</td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td>Technical Exhibition 09:00–17:00</td>
</tr>
</tbody>
</table>
### Preliminary Scientific Programme Schedule

**Wednesday, 20 June 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>S-43 Novel approaches in mechanisms of action of antidepressant treatment</td>
</tr>
<tr>
<td>9:00</td>
<td>S-44 Cannabinoid Receptor (CBR) gene variations in neuropsychiatric disorders</td>
</tr>
<tr>
<td>9:30</td>
<td>S-45 Behavioral Addictions: Diagnosis, co-morbidity and neurobiology</td>
</tr>
<tr>
<td>10:00</td>
<td>S-46 Neurobiology and psychopharmacology of aggressive behaviour: Where are we?</td>
</tr>
<tr>
<td>10:30</td>
<td>Plenary Lecture PL-03 Epigenetic consequences of early adversity: Implications for psychiatric disorders</td>
</tr>
<tr>
<td>11:00</td>
<td>D-03 Deep brain stimulation is a worthwhile treatment method in psychiatry</td>
</tr>
<tr>
<td>11:30</td>
<td>TFS-07 Enhancing the role of primary care in looking after people with mental health problems: A new position paper from the Collaborative...</td>
</tr>
<tr>
<td>12:00</td>
<td>S-48 Pharmacogenetics of drug defense and neuroprotection: From the Neandertal to the modern humans</td>
</tr>
<tr>
<td>12:30</td>
<td>S-49 Evidence-based guidelines for treatment of major depressive disorder: Contrasting views across the world</td>
</tr>
<tr>
<td>13:00</td>
<td>S-50 Real time assessment of psychopathology and behavior in Bipolar Disorder (BP) using e-mental health technologies</td>
</tr>
<tr>
<td>13:30</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td>14:00</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>S-51 Advances in biomarker development for neurostimulation</td>
</tr>
<tr>
<td>15:30</td>
<td>TFS-08 Men’s mental health: Contemorary aspects</td>
</tr>
<tr>
<td>16:00</td>
<td>TFW-03 WFSBP Treatment Guideline Session: Do bipolar mixed states merit a treatment guideline on its own?</td>
</tr>
<tr>
<td>16:30</td>
<td>S-52 The G protein coupled receptors as a target for psychotropic drugs</td>
</tr>
<tr>
<td>17:00</td>
<td>S-53 Suicidal behavior: Neuropsychological and genetic determinants</td>
</tr>
<tr>
<td>17:30</td>
<td>WS-09 Schizophrenia research in Chile</td>
</tr>
<tr>
<td>18:00</td>
<td>Satellite Symposia</td>
</tr>
</tbody>
</table>

**Registrations and Exhibitions**

- Registration Counter: 08:00 – 18:30
- Poster Exhibition: 09:00 – 17:00
- Technical Exhibition: 09:00 – 17:00
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>S-56 Clinical effects and neural mechanisms of electroconvulsive therapy in major depression and schizophrenia</td>
</tr>
<tr>
<td>9:00</td>
<td>S-57 Causes and consequences of inflammation in Bipolar Disorder (BP)</td>
</tr>
<tr>
<td>9:30</td>
<td>S-58 Novel therapeutics for neurodegenerative disorders</td>
</tr>
<tr>
<td>10:00</td>
<td>S-59 The relevance of Neuregulin1-ErbB4 signaling for neuropsychiatric pathomechanisms: Converging insights from mouse ...</td>
</tr>
<tr>
<td>10:30</td>
<td>S-60 Multi-omics and psychiatry: The missing molecular link</td>
</tr>
<tr>
<td>11:00</td>
<td>S-61 Suicide: Aspects that burn</td>
</tr>
<tr>
<td>11:30</td>
<td>Free Communications</td>
</tr>
<tr>
<td>12:00</td>
<td>Plenary Lecture</td>
</tr>
<tr>
<td></td>
<td>PL-04 Lithium in mood disorders including a homage to Danish contribution</td>
</tr>
<tr>
<td>12:30</td>
<td>Free Communications</td>
</tr>
<tr>
<td>13:00</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td>15:00</td>
<td>S-68 Dynamical brain: How brain complexity changes with aging and mental illness?</td>
</tr>
<tr>
<td>15:30</td>
<td>S-69 Increased intestinal permeability and bacterial translocation in neuro-psychiatric disorders</td>
</tr>
<tr>
<td>16:00</td>
<td>S-70 Current use of EEG-based techniques in psychiatry</td>
</tr>
<tr>
<td>16:30</td>
<td>S-71 Sex-specific neuromedical findings in conduct disorder</td>
</tr>
<tr>
<td>17:00</td>
<td>S-72 Socio-demographic and clinical differences between Bipolar I and II Disorder (BP) and implications for treatment</td>
</tr>
<tr>
<td>17:30</td>
<td>S-73 Neuropathologic implication of abnormal cortico-basal ganglia connectivity in schizophrenia hallucination and its models</td>
</tr>
<tr>
<td>18:00</td>
<td>Free Communications</td>
</tr>
<tr>
<td>18:30</td>
<td>Free Communications</td>
</tr>
</tbody>
</table>

Registration Counter 08:00–17:30
Poster Exhibition 09:00–17:00
## Opening Lecture

**Sunday, 18 June 2017**

**OP-01**
18:00–19:00
The microbiome-gut-brain axis: A key regulator of brain & behaviour across the lifespan  
Chair: Masatoshi Takeda, Japan  
Speaker: John F. Cryan, Ireland

## Plenary Lectures

**Monday, 19 June 2017**

**PL-01**
10:15–11:00
Drug discovery in neuroscience: Promises, barriers and opportunities  
Chair: Lakshmi Yatham, Canada  
Speaker: Husseini Manji, USA

**Tuesday, 20 June 2017**

**PL-02**
10:15–11:00
Novel treatments in mood disorders: Molecular mechanisms and clinical applications  
Chair: Gregers Wegener, Denmark  
Speaker: Carlos Zarate, USA

**Wednesday, 21 June 2017**

**PL-03**
10:15–11:00
Epigenetic consequences of early adversity: Implications for psychiatric disorders  
Chair: Constantin R. Soldatos, Greece  
Speaker: Elisabeth Binder, Germany

**Thursday, 22 June 2017**

**PL-04**
10:15–11:00
Lithium in mood disorders including a homage to Danish contribution  
Chair: Tudor Udristoiu, Romania  
Speaker: Janusz Rybakowski, Poland

## Debates

**Monday, 19 June 2017**

**D-01**
11:15–12:45
Antidepressants are effective for treating acute bipolar depression  
Chair: Lakshmi Yatham, Canada  
Proponent: Glenda MacQueen, Canada  
Opponent: Robert Post, USA

**Tuesday, 20 June 2017**

**D-02**
11:15–12:45
The Research Domain Criteria (RDoC) can create a new kind of taxonomy holding greater promise compared to the traditional Nosological Classification Systems in psychiatry  
Chair: Sabine Herpertz, Germany  
Proponent: Andreas Heinz, Germany  
Opponent: Henning Saß, Germany

**Wednesday, 21 June 2017**

**D-03**
11:15–12:45
Deep brain stimulation is a worthwhile treatment method in psychiatry  
Chair: Gregers Wegener, Denmark  
Proponent: Thomas Schläpfer, Germany  
Opponent: Marwan Hariz, United Kingdom
WFSBP Task Force Symposia

▶ Monday, 19 June 2017

T51: PSYCHOPHARMACOLOGY

TFS-01
11:15 – 12:45
Therapeutic drug monitoring, pharmacogenetics and brain imaging methods as tools for optimizing pharmacotherapy in psychiatry
Chair: Chin B. Eap, Switzerland
Co-Chair: Christoph Hiemke, Germany

TFS-01-001
Pharmacogenetics in psychiatry
Chin B. Eap, Switzerland

TFS-01-002
Therapeutic drug monitoring in psychiatry
Christoph Hiemke, Germany

TFS-01-003
Brain imaging in psychiatry
Gerhard Gründer, Germany

TFS-01-004
Strategies for the implementation of genetic biomarkers in clinical practice
Daniel Müller, Canada

T24: NEUROPATHOLOGY

TFS-02
15:00 – 16:30
Post-mortem findings across psychiatric disorders and their association with cognitive symptoms
Chair: Andrea Schmitt, Germany
Co-Chair: Johann Steiner, Germany

TFS-02-001
Alterations in hippocampal oligodendrocyte and neuron number in patients with schizophrenia, Bipolar Disorder (BP) and major depression
Peter Falkai, Germany

TFS-02-002
GABAergic system impairment in the hippocampus and superior temporal gyrus of patients with paranoid schizophrenia
Johann Steiner, Germany

TFS-02-003
Presynaptic contributions to cognitive reserve
William Honer, Canada

T22: MOLECULAR NEUROBIOLOGY

TFS-03
17:00 – 18:30
Update biomarkers in psychiatry
Chair: Peter Riederer, Germany
Co-Chair: Peter Falkai, Germany

TFS-03-001
Biomarkers for schizophrenia
Florence Thibaut, France

TFS-03-002
Biological marker in alcoholism
Toshikazu Saito, Japan

TFS-03-003
Specificity of biomarkers for OCD / ADHD
Edna Grünblatt, Switzerland

TFS-03-004
Specificity of biomarkers for anxiety
Borwin Bandelow, Germany

▶ Tuesday, 20 June 2017

T11: DEPRESSION: BASIC/CLINICAL

TFS-04
11:15 – 12:45
Sleep in depression and cognition – from research to clinical practice
Chair: Edith Holsboer-Trachsler, Switzerland
Co-Chair: Birendra N. Mallick, India

TFS-04-001
Sleep as biomarker: Predictor of emotional regulation and depression
Martin Hatzinger, Switzerland

TFS-04-002
Sleep in dementia: A biomarker of cognition?
Dimitris Dikeos, Greece

TFS-04-003
Sleep and synaptic dysfunction in depression
Anne Eckert, Switzerland

TFS-04-004
REM sleep and prevention of neurodegeneration: Role of noradrenaline
Birendra N. Mallick, India
**T43: SCHIZOPHRENIA: BASIC / CLINICAL**

**TFS-05**
15:00 – 16:30

Biomarkers for schizophrenia: From molecules to brain function. A consensus of the WFSBP Task Force on biological markers  
Chair: Andrea Schmitt, Germany  
Co-Chair: Daniel Martins de Souza, Brazil

**TFS-05-001**  
Genetic biomarkers  
Dan Rujescu, Germany

**TFS-05-002**  
Neuroimaging biomarkers  
Nikolaos Koutsouleris, Germany

**TFS-05-003**  
Molecular biomarkers  
Daniel Martins de Souza, Brazil

**TFS-05-004**  
Cognition biomarkers  
Peter Falkai, Germany

**T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)**

**TFS-06**  
17:00 – 18:30

Electroconvulsive therapy: Beyond depression  
Chair: Georgios Petrides, USA  
Co-Chair: William McDonald, USA

**TFS-06-001**  
ECT for the treatment of catatonia  
Tom Bolwig, Denmark

**TFS-06-002**  
ECT in autism spectrum disorders: Catatonia and beyond  
Lee Wachtel, USA

**TFS-06-003**  
ECT for agitation in elderly patients with dementia  
Adriana Hermida, USA

**TFS-06-004**  
ECT-related mortality rates  
Søren Dinesen Østergaard, Denmark

**Wednesday, 21 June 2017**

**T20: LIAISON PSYCHIATRY**

**TFS-07**  
11:15 – 12:45

Enhancing the role of primary care in looking after people with mental health problems: A new position paper from the Collaborative Care Task Force of the WFSBP  
Chair: Nick Kates, Canada

**TFS-07-001**  
Improving primary mental health care – Definitions, models, principles and challenges  
Nick Kates, Canada

**TFS-07-002**  
Integrating mental health services within primary care settings  
Henrikje Klasen, The Netherlands

**TFS-07-003**  
The role of the family physician in delivering mental health care  
Torleif Raud, Norway

**TFS-07-004**  
Capacity building, training and adapting the approach for different countries  
Nick Kates, Canada

**T51: MEN’S MENTAL HEALTH**

**TFS-08**  
15:00 – 16:30

Men’s mental health: Contemporary aspects  
Chair: Leo Sher, USA  
Co-Chair: Timothy Rice, USA

**TFS-08-001**  
Future research and clinical directions in the field of men’s mental health  
Leo Sher, USA

**TFS-08-002**  
Towards a neuropsychiatric model of disruptive behavior disorders in boys and young men: Developmental deficits in the emotion regulation system, their origin, and their therapeutic address  
Timothy Rice, USA

**TFS-08-003**  
Sex differences in addictive disorder and its clinical connotation  
Shih-Ku Lin, Taiwan
TFS-08-004  
Sex differences in early predictors of adult personality and intelligence  
Trine Flensborg-Madsen, Denmark

TFS-09-001  
Brain development: A focus on normal male development and psychopathology  
Pilar Trelles, USA

TFS-09-002  
Asking for the IM: What to do when the disruptive male child appears to seek punishment  
Timothy Rice, USA

TFS-09-003  
Aggression in adolescence  
Lesha Shah, USA

TFS-09-004  
Violent and suicidal behavior among young male veterans on an inpatient psychiatric unit  
Leo Sher, USA

WFSBP Task Force Workshops

► Monday, 19 June 2017  
T32: PHARMACOGENETICS

TFW-01  
15:00–16:30  
Workshop of the WFSBP Task Force on genetics: Focus on pharmacogenomics  
Chair: Dan Rujescu, Germany  
Co-Chair: Jim Kennedy, Canada

TFW-01-001  
Pharmacogenetics in schizophrenia  
Rainald Mössner, Germany

TFW-01-002  
Largest genome wide association study on agranulocytosis under Clozapine  
Dan Rujescu, Germany

TFW-01-003  
Whole exom sequencing reveals risk factors in treatment resistant depression  
Alessandro Serretti, Italy

TFW-01-004  
Pharmacogenetic discoveries and applications in psychiatric populations  
Jim Kennedy, Canada

► Tuesday, 20 June 2017  
T13: EMERGENCY PSYCHIATRY

TFW-02  
15:00–16:30  
WFSBP consensus on the management of agitation in psychiatry  
Chair: Siegfried Kasper, Austria  
Co-Chair: Eduard Vieta, Spain

TFW-02-001  
Agitation: Causes and differential diagnosis  
Marina Garriga, Spain

TFW-02-002  
Agitation in schizophrenia  
Dieter Naber, Germany

TFW-02-003  
Agitation in Bipolar Disorder (BP)  
Lakshmi Yatham, Canada

TFW-02-004  
WFSBP Consensus on agitation in psychiatry  
Eduard Vieta, Spain

► Wednesday, 21 June 2017  
T6: BIPOLAR DISORDERS: BASIC/CLINICAL

TFW-03  
15:00–16:30  
WFSBP Treatment Guideline Session: Do bipolar mixed states merit a treatment guideline on its own?  
Chair: Siegfried Kasper, Austria  
Co-Chair: Heinz Grunze, United Kingdom

TFW-03-001  
Clinical manifestations of bipolar mixed states-epidemiological and clinical research  
Jean-Michel Azorin, France

TFW-03-002  
The changing concept of mixed states over time: DSM5 broadening and downgrading at the same time  
Eduard Vieta, Spain
### TFW-03-003
The WFSBP Treatment guideline for mixed states—evidence and recommendations
Heinz Grunze, United Kingdom

### TFW-03-004
What the CINP guideline recommends in mixed states
Konstantinos Fountoulakis, Greece

## Symposia

### Sunday, 18 June 2017

### T2: ANTIDEPRESSANTS: BASIC / CLINICAL

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| S-01    | Towards novel rapid-acting antidepressants | Tomi Rantamäki, Finland  
Gregers Wegener, Denmark |
| S-01-001| Rapid acting antidepressants in chronic pain | Ipek Yalcin, France |
| S-01-002| Morphological and structural alterations following rapid acting antidepressants | Gregers Wegener, Denmark |
| S-01-003| Antidepressant potential of cannabidiol: Preclinical evidence | Sâmia Joca, Brazil |
| S-01-004| Anesthetics as rapid-acting antidepressants | Tomi Rantamäki, Finland |

### T20: LIAISON PSYCHIATRY

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| S-02    | Psychiatric services in emergency departments: Challenges and solutions | Ruby Castilla-Puentes, USA  
Tatiana Falcone, USA |
| S-02-001| Psychiatric consultations in rural general hospitals – Latinos vs. Anglos | Bernardo Ng, USA |
| S-02-002| A study of insomnia and comorbid psychiatric conditions in rehabilitation clinics | Franklin Escobar, Colombia |

### T1: ADDICTIVE DISORDERS

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-03</td>
<td>Dissecting the role of the neurotrophin Brain Derived Neurotrophic Factor in cocaine addiction: Clues from clinical and preclinical studies</td>
<td>Fabio Fumagalli, Italy</td>
</tr>
<tr>
<td>S-03-001</td>
<td>Acute exposure to cocaine during brain development evokes depressive-like behaviors via downregulation of Brain Derived Neurotrophic Factor signaling</td>
<td>Fabio Fumagalli, Italy</td>
</tr>
<tr>
<td>S-03-002</td>
<td>Cocaine and orbitofrontal cortical Brain Derived Neurotrophic Factor deficiency induce habit-based decision-making: Blockade by trkB stimulation</td>
<td>Shannon Gourley, USA</td>
</tr>
<tr>
<td>S-03-003</td>
<td>Systemic administration of the brain-penetrant TrkB antagonist cyclotraxin-b reduces short and long access cocaine intake</td>
<td>Michel Verheij, The Netherlands</td>
</tr>
<tr>
<td>S-03-004</td>
<td>Brain Derived Neurotrophic Factor and cocaine in clinical samples: A useful biomarker for treatment?</td>
<td>Lisia von Diemen, Brazil</td>
</tr>
</tbody>
</table>

### T6: BIPOLAR DISORDERS: BASIC / CLINICAL

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| S-04    | Pathways of neuroprogression in Bipolar Disorder (BP) | Benicio Frey, Canada  
Flavio Kapczinski, Brazil |
| S-04-001| Indicators or risk and resilience in the high-risk offspring of bipolar parents | Anne Duffy, Canada |
Preliminary Scientific Programme / Symposia

S-04-002
Lithium compared to quetiapine in the maintenance phase after a first episode of mania
Michael Berk, Australia

S-04-003
Biological rhythms and illness progression in Bipolar Disorder (BP)
Benicio Frey, Canada

S-04-004
Illness trajectories and neuroprogression in Bipolar Disorder (BP)
Flavio Kapczinski, Brazil

T22: MOLECULAR NEUROBIOLOGY

S-05
10:15 – 11:45
Extracellular vesicles in neuropsychiatric diseases: Basic mechanisms and biomarkers
Chair: Takashi Kudo, Japan
Co-Chair: Dimitrios Kapogiannis, USA

S-05-001
Extracellular vesicles as a source of biomarkers for Alzheimer’s Disease
Dimitrios Kapogiannis, USA

S-05-002
Tau inside neutrally-derived exosome
Dominic Walsh, USA

S-05-003
Mechanisms of exosome involvement in neurodegenerative diseases
Andrew Hill, Australia

S-05-004
Changes in exosomes proteins by the degree of stress
Takashi Kudo, Japan

T22: MOLECULAR NEUROBIOLOGY

S-06
10:15–11:45
Drug addiction and GPCR heteroreceptor complexes: What goes wrong in receptor plasticity as addiction develops?
Chair: Kjell Fuxe, Sweden
Co-Chair: Anita Hansson, Germany

S-06-001
Neurochemical mechanisms underlying goal-directed and habitual drug seeking and how these mechanisms produce compulsions: Focus on Gq-coupled glutamate receptors
Peter Kalivas, USA

S-06-002
Homo and heteroreceptor complexes participate in learning and memory and as an emerging target for treatment of cocaine addiction
Dasiel Borroto-Escuela, Sweden

S-06-003
Evidence for a role of A2A-D2 heteroreceptor complexes in cocaine addiction
Malgorzata Filip, Poland

S-06-004
Dopamine D4 –MOR interactions prevent nigrostriatal dopamine pathway activation by morphine: Relevance for drug addiction
Alicia Rivera, Spain

T43: SCHIZOPHRENIA: BASIC/CLINICAL

S-07
12:30–14:00
Social cognition and neuronal correlates in patients with schizophrenia
Chair: Gabriele Sachs, Austria
Co-Chair: Armida Mucci, Italy

S-07-001
Neurocognitive predictors of social cognition
Vijaya Lakshmi Valaparla, India

S-07-002
Emotional intelligence in patients suffering from schizophrenia and unaffected siblings
Alex Hofer, Austria

S-07-003
Social cognition and negative symptoms in schizophrenia: Constructs, assessment and relationships with functional outcome
Armida Mucci, Italy
S-07-004
Neurobiological correlates of the treatment of emotion processing in schizophrenia
Gabriele Sachs, Austria

T19: INFLAMMATION PSYCHIATRY
S-08
12:30–14:00
Inflammation markers of peripheral blood in depression spectrum
Chair: Piotr Galecki, Poland
Co-Chair: Angelos Halaris, USA

S-08-001
(Auto)immune biomarkers of depression and subtypes
Michael Maes, Thailand

S-08-002
Targeting inflammation to prevent depression
Michael Berk, Australia

S-08-003
Stratification of depressed patients by means of blood markers of inflammation, growth factors and kynurenine metabolites
Angelos Halaris, USA

S-08-004
Omega-3 fatty acids, inflammation and depression: From biological mechanisms to clinical application
Pin-Su Kuna, Taiwan

T39: PSYCHONEUROIMMUNOLOGY
S-09
14:30–16:00
Mechanisms contributing to neuroprogression in psychiatric disorders and promising interventions
Chair: Angelos Halaris, USA

S-09-001
Inflammatory and innate immune markers of neuroprogression in depressed and teenage suicide brain
Ghanshyam Pandey, USA

S-09-002
Major depression as a prelude to dementia: What is the evidence?
Brian Leonard, Ireland

S-09-003
Neuroimaging of microglia activation in major depression
Jeffrey Meyer, Canada

S-09-004
Promising neuroprotective and anti-inflammatory interventions to arrest neuroprogression
Angelos Halaris, USA

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)
S-10
14:30–16:00
Effects and side effects of electroconvulsive therapy
Chair: Michael Grözinger, Germany
Co-Chair: Helge Frieling, Germany

S-10-001
Effects of ECT on the oxygen saturation in the frontal brain
Michael Grözinger, Germany

S-10-002
DNA methylation of P11/S100A10: A putative marker of response to ECT?
Helge Frieling, Germany

S-10-003
Electroconvulsive therapy enhances amyloid β 1-42 in the cerebrospinal fluid of patients with major depression
Alexander Sartorius, Germany

S-10-004
The EFFECT-Dep Trial (ISRCTN23577151): Immediate and long-term cognitive outcomes
Declan McLoughlin, Ireland

T43: SCHIZOPHRENIA: BASIC/CLINICAL
S-11
14:30–16:00
Abnormal neurogenesis in schizophrenia
Chair: Dragos Inta, Germany
Co-Chair: Guo-Li Ming, USA

S-11-001
Modeling predisposition to schizophrenia using hiPSCs
Kristen Brennand, USA

S-11-002
Neurogenesis and psychiatric neurodevelopmental disorders
Guo-Li Ming, USA

S-11-003
Precise activation of the Reelin pathway controls dendritic maturation, synapse formation and glial ensheathment of adult-generated granule cells
Eduardo Soriano, Spain
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chair(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-11-004</td>
<td>Adult neurogenesis in the striatum: Effect of psychiatric treatment</td>
<td>Dragos Inta, Germany</td>
<td></td>
</tr>
<tr>
<td>T6: BIPOLAR DISORDERS: BASIC / CLINICAL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S-12</td>
<td>New approaches into diagnosis and treatment of psychotic Bipolar Disorder (BP)</td>
<td>Carlo Altamura, Italy; Allan Young, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>S-12-001</td>
<td>Neuroimaging aspects of psychotic Bipolar Disorder (BP)</td>
<td>Paolo Brambilla, Italy</td>
<td></td>
</tr>
<tr>
<td>S-12-002</td>
<td>Candidate biomarkers for psychotic Bipolar Disorder (BP): The role of neuroinflammation and hormones</td>
<td>Massimiliano Buoli, Italy</td>
<td></td>
</tr>
<tr>
<td>S-12-003</td>
<td>Pharmacological treatment of psychotic Bipolar Disorder (BP)</td>
<td>Trisha Suppes, USA</td>
<td></td>
</tr>
<tr>
<td>T10: DEMENTIA: BASIC / CLINICAL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S-13 SYMPOSIUM</td>
<td>Biomarkers for early diagnosis of Alzheimer's Disease (AD) and other neurodegenerating diseases: Advantages and limitations</td>
<td>Piotr Lewczuk, Germany; Henrik Zetterberg, Sweden</td>
<td></td>
</tr>
<tr>
<td>S-13-001</td>
<td>New developments in the biomarkers for Alzheimer's Disease (AD)</td>
<td>Kaj Blennow, Sweden</td>
<td></td>
</tr>
<tr>
<td>S-13-002</td>
<td>Amyloid beta 42/40 Ratio in diagnosis of AD: Do we need it?</td>
<td>Piotr Lewczuk, Germany</td>
<td></td>
</tr>
<tr>
<td>S-13-003</td>
<td>Sensitive technologies for blood biomarkers in neurodegeneration</td>
<td>Henrik Zetterberg, Sweden</td>
<td></td>
</tr>
<tr>
<td>S-13-004</td>
<td>Current diagnostic approaches in frontotemporal lobar degeneration</td>
<td>Markus Otto, Germany</td>
<td></td>
</tr>
<tr>
<td>MONDAY, 19 JUNE 2017</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1: ADDICTIVE DISORDERS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S-14</td>
<td>Problematic sexual behaviors: Diagnostic, categorical, epidemiological, imaging, psychopathological and treatment considerations</td>
<td>Marc Potenza, USA; Florence Thibaut, France</td>
<td></td>
</tr>
<tr>
<td>S-14-001</td>
<td>Classification and clinical issues relating to hypersexuality</td>
<td>Marc Potenza, USA; S. Kraus</td>
<td></td>
</tr>
<tr>
<td>S-14-002</td>
<td>Sexual impulsivity, psychopathology and trauma: Gender-related differences</td>
<td>Galit Erez, Israel</td>
<td></td>
</tr>
<tr>
<td>S-14-003</td>
<td>Advances in pharmacological treatments for sex offenders</td>
<td>Florence Thibaut, France</td>
<td></td>
</tr>
<tr>
<td>S-14-004</td>
<td>Neurobiology of compulsive sexual behaviors</td>
<td>Valerie Voon, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>T35: POSTTRAUMATIC STRESS: BASIC / CLINICAL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S-15</td>
<td>Posttraumatic Stress Disorder (PTSD) and gender</td>
<td>Hans-Jürgen Möller, Germany; Victoria Valdez, Ecuador</td>
<td></td>
</tr>
<tr>
<td>S-15-001</td>
<td>Clinical issues: PTSD and gender violence</td>
<td>Victoria Valdez, Ecuador</td>
<td></td>
</tr>
<tr>
<td>S-15-002</td>
<td>Course and prognosis PTSD</td>
<td>Kayihan Oguz Karamustafa, Turkey</td>
<td></td>
</tr>
<tr>
<td>S-15-003</td>
<td>Biological aspects and PTSD</td>
<td>Soraya Seedat, South Africa</td>
<td></td>
</tr>
<tr>
<td>S-15-004</td>
<td>Genetics and PTSD</td>
<td>Sian Hermann, South Africa</td>
<td></td>
</tr>
</tbody>
</table>
T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-16
08:30–10:00
The elephant in the room: The role of glial cells in psychiatric disorders
Chair: Sabina Berretta, USA
Co-Chair: Mikhail Pletnikov, USA

S-16-001
Psychiatric genetic risk factors in healthy and diseased astrocytes
Mikhail Pletnikov, USA

S-16-002
Glia-extracellular matrix interactions in the pathophysiology of schizophrenia and Bipolar Disorder (BD)
Sabina Berretta, USA

S-16-003
Abnormalities of glutamate transporter localization in severe mental illness
Robert McCullumsmith, USA

S-16-004
Evidence for neuroinflammation, gliosis and leaky brain in people with schizophrenia
Cyndi Shannon Weickert, Australia

T49: SUICIDE: BASIC / CLINICAL

S-18
08:30–10:00
Epigenetic modification, effect of early life stress, and signaling mechanisms in suicide
Chair: Ghanshyam Pandey, USA
Co-Chair: Victoria Arango, USA

S-18-001
Impact of the early-life environment on the epigenetic regulation of the anterior cingulate gyrus
Gustavo Turecki, Canada

S-18-002
Expression and methylation of glucocorticoid receptors and FKBP5 in teenage and adult suicide
Ghanshyam Pandey, USA

S-18-003
Genome-wide epigenetic changes in suicide attempters
Jussi Jokinen, Sweden

S-18-004
5-HT1A receptor anti-apoptotic transduction pathways in suicide
Victoria Arango, USA

T11: DEPRESSION: BASIC / CLINICAL

S-19
08:30–10:00
Psychedelics: Mechanisms and applications in psychiatry
Chair: Tomas Palenicek, Czech Republic
Co-Chair: Franz X. Vollenweider, Switzerland

S-19-001
Role of 5-HT2A receptors in the mechanism of action of psilocybin and LSD and the treatment of affective disorders
Franz X. Vollenweider, Switzerland

S-19-002
The effect of psilocybin on brain connectivity and emotional processing in healthy volunteers
Tomas Palenicek, Czech Republic

S-19-003
Psilocybin for the treatment of depression
Robin Carhart-Harris, United Kingdom
S-19-004
Exploring the therapeutic potential of ayahuasca in the treatment of psychiatric disorders
Jordi Riba, Spain

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC/CLINICAL
S-20
08:30–10:00
Affective and psychotic psychopathology from pregnancy to early adulthood: The dynamic developmental interplay between genes, structures and functions
Chair: Paolo Brambilla, Italy
Co-Chair: Michael Kaess, Germany

S-20-001
Can personality and parental care impact on brain development?
Paolo Brambilla, Italy

S-20-002
Neurodevelopmental trajectories and psychopathology in adolescents and adults who were born very preterm
Chiara Nosarti, United Kingdom

S-20-003
Grin2b mediates susceptibility to affective problems in children and adolescents
Maria Nobile, Italy

S-20-004
Corollary discharge auditory hallucinations and schizophrenia: A structural network analysis
Romy Hemze, Germany

T11: DEPRESSION: BASIC/CLINICAL
S-21
11:15–12:45
Measurement-based psychiatry: Toward rating scale-based assessments in the real world
Chair: Christoph U. Correll, USA
Co-Chair: Søren Dinesen Østergaard, Denmark

S-21-001
Measurement-based care psychiatry: Where are we at and where should we head?
Andrew A. Nierenberg, USA

S-21-002
Measurement-based care versus standard care for major depression: Conducting a success randomized controlled trial with blind raters
Christoph U. Correll, USA

S-21-003
The role for measurement-based care for bipolar disorder in current and future clinical practice
Eduard Vieta, Spain

S-21-004
PANSS-6: A new rating scale for both research and clinical care in schizophrenia
Søren Dinesen Østergaard, Denmark
S-23-002
Short-term working memory training for individuals with psychosis: Cognitive and neurophysiological effects
Christopher Bowie, Canada

S-23-003
Randomised trial of low support cognitive training for schizophrenia: Cortical and behavioural outcomes
Gary Donohoe, Ireland

S-23-004
SESAME: A brief intervention for memory in schizophrenia. Behavioral and imaging data
Martin Lepage, Canada

T4: ANXIETY DISORDERS: BASIC/CLINICAL

S-24
11:15 – 12:45
Serotonin and anxiety disorders: Recent evidences from neuroimaging studies
Chair: Eduard Maron, Estonia
Co-Chair: Tomas Furmark, Sweden

S-24-001
Serotonin system and panic disorder
Eduard Maron, Estonia

S-24-002
Serotonin system and social anxiety disorder
Tomas Furmark, Sweden

S-24-003
Serotonin system and obsessive-compulsive disorder
Oliver Pogarell, Germany

S-24-004
Serotonin regulation of anxiety neuronal network
Andreas Frick, Sweden

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-25
15:00 – 16:30
tDCS: From research to clinical practice
Chair: Emmanuel Poulet, France
Co-Chair: Jerome Brunelin, France

S-25-001
Translational research on tDCS: Data from a German multisite project
Frank Padberg, Germany

S-25-002
Combining tDCS with neuroimaging
Shirley Fecteau, Canada

S-25-003
Effects of tDCS on biological reactivity to stress and decision making
Jerome Brunelin, France

T33: PHARMACOLOGY

S-26
15:00 – 16:30
Into novel drugs for depression
Chair: Erich Seifritz, Switzerland

S-26-001
Conceptual strategies of Big Pharma into innovation in psychiatric therapies: Future leads
Siegfried Kasper, Austria

S-26-002
Personalizing psychiatry treatment
Florian Holsboer, Germany

S-26-003
Psychedelic drugs and clinical markers as innovation road to psychopharmacotherapy
Franz X. Vollenweider, Switzerland

S-26-004
GHB as a candidate drug for stratified depression subtypes
Oliver G. Bosch, Switzerland

T43: SCHIZOPHRENIA: BASIC/CLINICAL

S-27
15:00 – 16:30
Beyond unitary models of psychosis: Confronting complex etiology and dimensionality
Chair: Mikhail Pletnikov, USA
Co-Chair: John Waddington, Ireland

S-27-001
Recognising the dimensionality of psychotic illness: Broadening the phenotype to the affective domain
Catherine Belzung, France

S-27-002
Addressing the translational challenge of etiological diversity: Complex gene-environment interactions in risk for psychosis
Mikhail Pletnikov, USA
T11: DEPRESSION: BASIC/CLINICAL

S-28
15:00 – 16:30
Wake and sleep electroencephalogramm provide biomarkers of depression
Chair: Axel Steiger, Germany
Co-Chair: Thorsten Mikoteit, Switzerland

S-28-001
Central and autonomous nervous system activity in the prediction of antidepressant treatment
Sebastian Olbrich, Switzerland

S-28-002
The value of prefrontal theta cordance of resting EEG in the prediction of antidepressant response
Martin Brunovsky, Czech Republic

S-28-003
Novel REM-sleep derived biomarkers of depression
Thorsten Mikoteit, Switzerland

S-28-004
sLORETA derived from REM sleep EEG as biomarkers for treatment response in depression after antidepressant medication
Marcel Pawlowski, Germany

S-27-003
Closing the translational gap between heritability and genetics: Complex gene-gene interactions in risk for psychosis
John Waddington, Ireland

S-27-004
Extending the strategy for translation: Human induced pluripotent stem cells
Kristen Brennand, USA

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC/CLINICAL

S-29
17:00 – 18:30
Autism spectrum disorders in adults – from the clinical phenotype to the underlying neurobiology – novel techniques such as phenotype-based genetic variants association studies, high field magnet resonance imaging and 3d brain organoids
Chair: Tanja Michel, Denmark
Co-Chair: Sophia Frangou, USA

S-29-001
On the outcome, time course and clinical presentation of autism in adults: A longitudinal study of clinical trajectories
Marlene Bricet Lauritsen, Denmark

S-29-002
Modulation of the autistic phenotypes in the broader fragile X gene family by accumulated common gene variants
Hannelore Ehrenreich, Germany

S-29-003
New insights from proteomics and nanotechnology-3 D brain organoids: A promising new tool for an in vitro model for ASD
Tanja Michel, Denmark

S-29-004
The role of myelination in neurodevelopmental disorders
Sophia Frangou, USA

T43: SCHIZOPHRENIA: BASIC/CLINICAL

S-30
08:30 – 10:00
Recent insights in schizophrenia physiopathology and treatments
Chair: Pierre-Michel Llorca, France
Co-Chair: Guillaume Fond, France

S-30-001
Bridging the gap between research and clinical practice: The development of a national network of schizophrenia expert centers
Guillaume Fond, France

S-30-002
Schizophrenia pathophysiology: Recent insights from neuroimaging on glutamatergic and neuroinflammatory mechanisms
Oliver Howes, United Kingdom
S-30-003
The influence of hormones on schizophrenia
Iris Sommer, The Netherlands

S-30-004
Novel adjunctive therapy approaches for inflammatory disturbances in psychiatric disorders
Michael Berk, Australia

T43: SCHIZOPHRENIA: BASIC/CLINICAL

S-31
08:30–10:00
Duration of untreated psychosis: From neuroimaging to clinical trials
Chair: John Kane, USA
Co-Chair: Erika Jaaskelainen, Finland

S-31-001
Is DUP a moderator of effectiveness with comprehensive specialty care in first episode schizophrenia?
John Kane, USA

S-31-002
The impact of DUP on short and long term outcomes in schizophrenia
Erika Jaaskelainen, Finland

S-31-003
Is there a relationship between DUP and brain structure?
Aristotle Voineskos, Canada

S-31-004
MRI resting state functional connectivity and DUP
Deepak Sarpal, USA

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-32
08:30–10:00
New perspectives on transcranial magnetic stimulation in psychiatric disorders
Chair: Shinsuke Kito, Japan
Co-Chair: Motoaki Nakamura, Japan

S-32-001
Transcranial magnetic stimulation in the treatment of bipolar depression
Shinsuke Kito, Japan

S-32-002
Clinical and neurobiological effects of Quadripulse Stimulation (QPS) and Theta Burst Stimulation (TBS) in Mood Disorders (MD)
Motoaki Nakamura, Japan

S-32-003
Neuropsychological correlates of various transcranial magnetic stimulation paradigms in patients with psychiatric disorders: In search of novel biomarkers
Yoshihiro Noda, Japan

S-32-004
Combination of computerized cognitive remediation and transcranial magnetic stimulation
Akihiro Takamiya, Japan

T11: DEPRESSION: BASIC/CLINICAL

S-33
08:30–10:00
Epigenetic biomarkers for the diagnosis of mood disorders
Chair: Tetsuro Ohmori, Japan
Co-Chair: Lourdes Fañanás, Spain

S-33-001
DNA methylation profiles of the Brain-derived Neurotrophic Factor (BDNF) gene as a potent diagnostic biomarker in major depression
Manabu Fuchikami, Japan

S-33-002
Antenatal prediction of postpartum depression with blood DNA methylation biomarkers
Zachary Kaminsky, USA

S-33-003
Blood diagnostic biomarkers for major depressive disorder using multiplex DNA methylation profiles
Shusuke Numata, Japan

S-33-004
Differential methylation and variable methylation in depression: A genome-wide analysis of monozygotic twins
Aldo Cordova-Palomera, Spain

T40: PSYCHOPATHOLOGY

S-34
08:30–10:00
Sex hormones and their wide-ranging effects on psychopathology
Chair: Andrea Gogos, Australia
Co-Chair: Mark Geyer, USA

S-34-001
Estrogen, raloxifene and schizophrenia
Cyndi Shannon Weickert, Australia
S-34-002
Cortical gene expression changes underlying estrogen's effect in schizophrenia
Andrea Gogos, Australia

S-34-003
17b-estradiol effects on psychosis-like attentional abnormalities in rats
Ina Weiner, Israel

S-34-004
Sex differences in depression: The role of neuroestrogens
Christina Dalla, Greece

T27: OBSESSIVE-COMPULSIVE DISORDERS: BASIC/CLINICAL

S-35
08:30–10:00
New insights into the neurobiology and treatment aspects of obsessive compulsive disorder comorbid with schizophrenia and bipolar affective disorder
Chair: E. Mohandas, India
Co-Chair: Narayan R. Mutalik, India

S-35-001
Neurobiology of obsessive compulsive disorder comorbid with schizophrenia
Narayan R. Mutalik, India

S-35-002
Evidence based management of obsessive compulsive disorder comorbid with schizophrenia
Firoz Kazhungil, India

S-35-003
Neurobiology of obsessive compulsive disorder comorbid with bipolar disorder
Rajan Nishanth Jayarajan, Australia

S-35-004
Recent updates in the management of obsessive compulsive disorder comorbid with Bipolar Disorder (BP)
Pawan Sharma, Nepal

T9: COGNITIVE NEUROSCIENCE

S-36 SYMPOSIUM
11:15–12:45
The role of the nucleus accumbens in psychiatry
Chair: Jens Kuhn, Germany
Co-Chair: Leonhard Schilbach, Germany

S-36-001
The anatomy of the nucleus accumbens
Ioannis Mavridis, Greece

S-36-002
The role of nucleus accumbens in social cognition
Leonhard Schilbach, Germany

S-36-003
The role of nucleus accumbens in impulsivity
Valerie Voon, United Kingdom

S-36-004
Deep brain stimulation of the nucleus accumbens
Sina Kohl, Germany

T11: DEPRESSION: BASIC/CLINICAL

S-37
11:15–12:45
Neurobiologic imaging studies of mood disorders, neurogenetics and antidepressant action with positron emission tomography
Chair: J. John Mann, USA
Co-Chair: Gitte Moos Knudsen, Denmark

S-37-001
Familial transmission of 5-HT1A autoreceptor up-regulation: An impaired serotonergic endophenotype in mood disorders
J. John Mann, USA

S-37-002
Molecular neuroimaging and genetics
Gitte Moos Knudsen, Denmark

S-37-003
cAMP Cascade in major depressive disorder: Downregulation in unmedicated patients and normalization with treatment
Robert Innis, USA

S-37-004
Predictiveness of peripheral and clinical markers for PET measurement of inflammation and monoamine oxidase: Implications for biomarker development
Jeffrey Meyer, Canada

T43: SCHIZOPHRENIA: BASIC/CLINICAL

S-38
11:15–12:45
Treatment resistant schizophrenia: Definitions, psychobiology and clinical treatment
Chair: John Kane, USA
Co-Chair: Ofer Agid, Canada

S-38-001
Methodological issues in clinical trial designs for TRS
John Kane, USA
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-38-002</td>
<td>A longitudinal perspective on the evolution of treatment resistance</td>
<td>Ofer Agid, Canada</td>
</tr>
<tr>
<td>S-38-003</td>
<td>The biology of treatment resistance</td>
<td>Oliver Howes, United Kingdom</td>
</tr>
<tr>
<td>S-38-004</td>
<td>Definitions and epidemiology of treatment resistance</td>
<td>Christoph U. Correll, USA</td>
</tr>
<tr>
<td>S-39-001</td>
<td>Cannabis use disorder and its effects on cognitive function</td>
<td>Valerie Curran, United Kingdom</td>
</tr>
<tr>
<td>S-39-002</td>
<td>The relationship between cannabis and psychosis</td>
<td>Deepak Cyril D’Souza, USA</td>
</tr>
<tr>
<td>S-39-003</td>
<td>The genetics of cannabis use disorder</td>
<td>Amine Benyamina, France</td>
</tr>
<tr>
<td>S-39-004</td>
<td>The effects of chronic use of synthetic cannabinoids on executive brain function</td>
<td>Aviv Weinstein, Israel</td>
</tr>
<tr>
<td>S-40-001</td>
<td>Pharmacogenetics of cerebrovascular phenotypes of risk in dementia</td>
<td>Ramon Cacabelos, Spain</td>
</tr>
<tr>
<td>S-40-002</td>
<td>Insulin resistance in neurodegeneration: The role of p53/miRNA/SIRT1 axis</td>
<td>Kazimierz Gasiorowski, Poland</td>
</tr>
<tr>
<td>S-40-003</td>
<td>Alzheimer drug discovery: Targeting synaptic glutamate signaling</td>
<td>Markku Kurkinen, USA</td>
</tr>
<tr>
<td>S-40-004</td>
<td>Nanotechnology for early detection and treatment of Alzheimer's Disease (AD): Where we stand and where we go</td>
<td>Jerzy Leszek, Poland</td>
</tr>
<tr>
<td>T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)</td>
<td>Electroconvulsive therapy for depression – optimising treatment and maintaining recovery</td>
<td>Declan McLoughlin, Ireland</td>
</tr>
<tr>
<td>S-41-001</td>
<td>The KEEP-WELL Trial: Ketamine for depression relapse prevention following ECT (NCT02414932)</td>
<td>Declan McLoughlin, Ireland</td>
</tr>
<tr>
<td>S-41-002</td>
<td>Immediate and long-term outcomes for Brief-pulse (BP) vs Ultrabrief-pulse (UBP) high-dose unilateral ECT: The ResPECT trials’ experience</td>
<td>Pascal Sienaert, Belgium, H.-P. Spaans, E. Verwijk, F. Bouckaert</td>
</tr>
<tr>
<td>S-41-003</td>
<td>Pre- and post-ECT cognitive performance as predictors for outcome and relapse in depression (NTR1304)</td>
<td>Esmée Verwijk, The Netherlands</td>
</tr>
<tr>
<td>S-41-004</td>
<td>The PRIDE Trial – Prolonging remission in depressed elderly (NCT01028508): Results from the randomised phase</td>
<td>Charles Kellner, USA</td>
</tr>
<tr>
<td>T22: MOLECULAR NEUROBIOLOGY</td>
<td>Neuroepigenetic approaches to assess disease risk, mechanism and treatment</td>
<td>Alfonso Bull, Denmark</td>
</tr>
<tr>
<td>S-42-001</td>
<td>CACNA1C hypermethylation associated with Bipolar Disorder (BD)</td>
<td>Anna Starnawska, Denmark, D. Demontis, A. Pen, A. Hedemand, A. L. Nielsen,</td>
</tr>
</tbody>
</table>

**S-42-002**

**Epigenomic trajectories across human brain development: Relevance for schizophrenia and other neurodevelopmental disorders**  
Jonathan Mill, United Kingdom

**S-42-003**

**Neonatal epigenetic profiling in Danish twins discordant for psychiatric disorder**  
Shantel Weinsheimer, Denmark  

**S-42-004**

**Epigenetics in schizophrenia and association with antipsychotic response to clozapine**  
Marta Bosia, Italy

**Wednesday, 21 June 2017**

**T2: ANTIDEPRESSANTS: BASIC / CLINICAL**

**S-43**

08:30–10:00  
**Novel approaches in mechanisms of action of antidepressant treatment**  
Chair:  Rainer Rupprecht, Germany

**S-43-001**

**Signal transduction in membranes as mechanism of action of antidepressants**  
Mark Rasenick, USA

**S-43-002**

**Cytoskeleton as target for antidepressants**  
Massimiliano Bianchi, Ireland

**S-43-003**

**Biomarkers during antidepressant treatment**  
Thomas Baghai, Germany

**S-43-004**

**Relevance of P-Glycoprotein and blood brain barrier for antidepressant treatment**  
Carmine Pariante, United Kingdom

**S-44**

08:30–10:00  
**Cannabinoid Receptor (CBR) gene variations in neuropsychiatric disorders**  
Chair:  Hiroki Ishiguro, Japan  
Co-Chair:  Emmanuel Onaivi, USA

**S-44-001**

**Environmental stressors induce psychosis based on genetic variation of CB2Rs**  
Hiroki Ishiguro, Japan

**S-44-002**

**ECB system alteration in an animal model of autism spectrum disorders**  
Eugene Dennis, USA

**S-44-003**

**Species differences in CBR genes**  
Qing-Rong Liu, USA

**S-44-004**

**CBR genetics: From mice to human subjects**  
Emmanuel Onaivi, USA

**T1: ADDICTIVE DISORDERS**

**S-45**

08:30–10:00  
**Behavioral addictions: Diagnosis, co-morbidity and neurobiology**  
Chair:  Michel Lejoyeux, France  
Co-Chair:  Aviv Weinstein, Israel

**S-45-001**

**Internet gaming disorder- addiction, co-morbidity and the brain**  
Aviv Weinstein, Israel

**S-45-002**

**Neuroimaging evidence for considering hypersexuality as an addiction**  
Florence Thibaut, France

**S-45-003**

**New data on phenomenology and psychiatric comorbidity of compulsive buying**  
Michel Lejoyeux, France

**S-45-004**

**The genetic background of gambling behavior**  
Zsolt Demetrovics, Hungary  
T50: VIOLENCE: BASIC / CLINICAL

S-46
08:30–10:00
Neurobiology and psychopharmacology of aggressive behaviour: Where are we?
Chair: Stefano Comai, Italy
Co-Chair: Gabriella Gobbi, Canada

S-46-001
Neurobiology and biomarkers of aggression
Stefano Comai, Italy

S-46-002
Clinical management of aggression in childhood and adolescence
Florian D. Zepf, Australia

S-46-003
Drug abuse/dependence and aggressive behaviour
Gabriella Gobbi, Canada

S-46-004
Epilepsy, antiepileptic drugs and aggression
Martin J. Brodie, United Kingdom

T11: DEPRESSION: BASIC / CLINICAL

S-47
08:30–10:00
Catecholamines, anhedonia and depression
Chair: Jose Luis Ayuso, Spain
Co-Chair: Victoria Valdez, Ecuador

S-47-001
Catecholamines, reward circuits and depression
Gregor Hasler, Switzerland

S-47-002
Positive affects and depression
Jorge Tellez-Vargas, Colombia

S-47-003
Anhedonia and suicide behavior
Maurizio Pompili, Italy

S-47-004
Exploring the role of proinflammatory cytokines in anhedonia
Ruby Castilla-Puentes, USA

T32: PHARMACOGENETICS

S-48
11:15–12:45
Pharmacogenetics of drug defense and neuroprotection: From the Neandertal to the modern humans
Chair: Julia Stingl, Germany
Co-Chair: Magnus Ingelman-Sundberg, Sweden

S-48-001
The evolutionary aspect of trait biomarkers in drug metabolism and neuroprotection
Magnus Ingelman-Sundberg, Sweden

S-48-002
Pharmacogenetic polymorphisms on behavioral and structural brain phenotypes uncovered by neuroimaging data
Roberto Viviani, Austria

S-48-003
Prevention of drug toxicity to the brain: The vulnerable brain and ADRs of nervous system disorders
Julia Stingl, Germany

S-48-004
Pharmacogenetic factors in neuroprotection during neurodevelopment
Karim Barakat, Germany

T11: DEPRESSION: BASIC / CLINICAL

S-49
11:15–12:46
Evidence-based guidelines for treatment of major depressive disorder: Contrasting views across the world
Chair: Roumen Milev, Canada
Co-Chair: Allan Young, United Kingdom

S-49-001
A subequatorial view: The new RANZCP guidelines
Gin Malhi, Australia

S-49-002
The evolution of the CANMAT guidelines
Raymond Lam, Canada

S-49-003
The view from the UK: BAP guidelines for Mood Disorders (MD)
Allan Young, United Kingdom

S-49-004
Even the best guidelines don’t work unless they are implemented
Sagar Parikh, USA
WFSBP 2017

Preliminary Scientific Programme / Symposia

**T6: BIPOLAR DISORDERS: BASIC / CLINICAL**

**S-50**
11:15 – 12:45
Real time assessment of psychopathology and behavior in Bipolar Disorder (BP) using e-mental health technologies
Chair: Lars Kessing, Denmark
Co-Chair: Michael Bauer, Germany

**S-50-001**
Mood instability and Bipolar Disorder (BD): Deriving useful biosignatures from multidimensional, time stamped, streamed data
John Geddes, United Kingdom

**S-50-002**
Smartphone based ambulatory assessment of early warning signs in Bipolar Disorder (BP)
Michael Bauer, Germany

**S-50-003**
Smartphones as objective electronic behavioral biomarkers of illness activity in Bipolar Disorder (BP)
Lars Kessing, Denmark

**S-50-004**
Voice recognition as objective electronic behavioral biomarkers of illness activity in Bipolar Disorder (BP)
Maria Fauerholt-Jepsen, Denmark

**T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)**

**S-51**
15:00 – 16:30
Advances in biomarker development for neurostimulation
Chair: Paul Croarkin, USA
Co-Chair: Motoaki Nakamura, Japan

**S-51-001**
Stimulation-induced neuroplasticity of prefrontal cortex in adult autism spectrum disorder
Motoaki Nakamura, Japan

**S-51-002**
Glutamatergic biomarker development for repetitive transcranial magnetic stimulation
Paul Croarkin, USA

**S-51-003**
Neurocognitive effects of major depressive disorder and neurostimulation therapies
Shawn McClintock, USA

**T3: ANTIPSYCHOTICS: BASIC/CLINICAL**

**S-52**
15:00 – 16:30
The G protein coupled receptors as a target for psychotropic drugs
Chair: Andrzej Pilc, Poland
Co-Chair: Jeffrey P. Conn, USA

**S-52-001**
Positive allosteric modulators of GPCRs as a novel treatment for schizophrenia
Jeffrey P. Conn, USA

**S-52-002**
The mGlu5 receptor imaging in schizophrenia and depression
Gregor Hasler, Switzerland

**S-52-003**
The mGlu2/3 receptor as a novel therapeutic target for treatment-resistant depression
Shigeyuki Chaki, Japan

**S-52-004**
The allosteric modulation of group III mGlu receptors as target for antipsychotic or antidepressant drugs
Andrzej Pilc, Poland

**T49: SUICIDE: BASIC/CLINICAL**

**S-53**
15:00 – 16:30
Suicidal behavior: Neurobiological and genetic determinants
Chair: Yogesh Dwivedi, USA

**S-53-001**
Epigenetic modifications in brain of suicide individuals: Focus on global and site-specific changes in 5-hydroxymethylcytosine
Gustavo Turecki, Canada

**S-53-002**
Genetics of intermediate phenotypes for suicidal behavior: Focus on impulsivity and aggression
Dan Rujescu, Germany

**S-53-003**
Toxoplasmagondii seropositivity and suicidal behavior
Teodor Postalache, USA
**S-53-004**
Non-coding RNAs: Novel epigenetic regulators in suicidal behavior
Yogesh Dwivedi, USA

**T51: PSYCHOPHARMACOLOGY**

**S-54**

17:00–18:30
Lithium as a neuroprotective agent: When and how?
*Chair:* Galila Agam, Israel  
*Co-Chair:* Changlian Zhu, People’s Republic of China

**S-54-001**
In vivo lithium-induced augments mitochondrial function, reduces neuroinflammation and increases autophagy
Galila Agam, Israel

**S-54-002**
Lithium as a novel approach to treat developing brain injury
Changlian Zhu, China, People’s Republic of

**S-54-003**
Hui Zhang, USA

**S-54-004**
Francoise Croute, France

**T23: MOOD STABILISERS: BASIC/CLINICAL**

**S-55**

17:00–18:30
Rediscovering Lithium
*Chair:* David Taylor, United Kingdom  
*Co-Chair:* Jonathan Meyer, USA

**S-55-001**
The evidence for Lithium’s antisuicide properties and impact on mortality
Jimmi Nielsen, Denmark

**S-55-002**
The evidence for Lithium’s neuroprotective properties
Barrat Luft, United Kingdom

**S-55-003**
What is the risk for end stage renal disease with Lithium: A sophisticated review
Ursula Wernike, Sweden  
M. Ott, E. Salander Renberg, B. Stegmayr

**S-55-004**
An update on assessing and managing Lithium’s renal effects
Jonathan Meyer, USA

**Thursday, 22 June 2017**

**T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)**

**S-56**

08:30–10:00
Clinical effects and neural mechanisms of electroconvulsive therapy in major depression and schizophrenia
*Chair:* Robert Christian Wolf, Germany  
*Co-Chair:* Philipp Thomann, Germany

**S-56-001**
ECT in major depression and schizophrenia: Indications and clinical effects
Dusan Hirjak, Germany

**S-56-002**
Effects of ECT on brain structure and function: Lessons from major depressive disorder
Robert Christian Wolf, Germany

**S-56-003**
ECT-related effects on regional brain volume and structural networks in patients with schizophrenia and major depressive disorder
Philipp Thomann, Germany

**S-56-004**
Modulation of intrinsic network connectivity by ECT in patients with schizophrenia and major depressive disorder
Fabio Sambataro, Italy

**T6: BIPOLAR DISORDERS: BASIC/CLINICAL**

**S-57**

08:30–10:00
Causes and consequences of inflammation in Bipolar Disorder (BP)
*Chair:* Lars Kessing, Denmark  
*Co-Chair:* Flavio Kapczinski, Brazil

**S-57-001**
Peripheral inflammation in Bipolar Disorder (BP): Trait and state related alterations
Klaus Munkholm, Denmark

**S-57-002**
Targeting mitochondrial inflammation in Bipolar Disorder (BP)
Ana Andreazza, Canada

**S-57-003**
Relationships between inflammation, elevated body mass index, and depressive relapse in Bipolar Disorder (BP)
David Bond, USA
Preliminary Scientific Programme / Symposia

S-57-004
Genetic and central nervous system aspects of immune dysregulation in Bipolar Disorder (BP)
Bartholomeus Haarman, The Netherlands

T51: NEURODEGENERATIVE DISORDERS

S-58
08:30–10:00
Novel therapeutics for neurodegenerative disorders
Chair: Ramon Cacabelos García, Spain

S-58-001
ASS234, as a new multi-target directed propargylamine for Alzheimer’s Disease (AD) therapy
José Marco-Contelles, Spain

S-58-002
EB101 immunotherapy against amyloid: A promising strategy for treating Alzheimer’s Disease (AD)
Ivan Carrera, Spain

S-58-003
The Intelligent Pharmacogenetic Card (PGx-iCard) for neuropsychiatric disorders
Juan C. Carril, Spain

S-58-004
Neuroprotective effects of Atremorine in Cerebral Ischemia and Parkinson disease-related models
Javier Egea, Spain

S-58-005
Basic and clinical studies with E-PodoFavalin-15999 (Atremorine®) in Parkinson’s Disease: Selective dopaminergic neuroprotection and pharmacogenetics
Ramon Cacabelos, Spain

T22: MOLECULAR NEUROBIOLOGY

S-59
08:30–10:00
The relevance of Neuregulin1-ErbB4 signaling for neuropsychiatric pathomechanisms: Converging insights from mouse genetics, physiology, and human studies
Chair: Peter Falkai, Germany
Co-Chair: Moritz Rossner, Germany

S-59-001
The relevance of Neuregulin1-ErbB4 signaling for neuropsychiatric pathomechanisms: Insights from human studies
Cyndi Shannon Weickert, Australia

S-59-002
Neuregulin1-ErbB4 signaling: Integration at the network level
Beatriz Rico, United Kingdom

S-59-003
The relevance of Neuregulin1-ErbB4: Insights from mouse physiological analyses
Andrés Buonanno, USA

S-59-004
Neuregulin1-ErbB4 signaling: Insights from mouse genetics
Markus Schwab, Germany

T49: SUICIDE: BASIC/CLINICAL

S-61
08:30–10:00
Suicide: Aspects that burn
Chair: Konstantinos Fountoulakis, Greece
Co-Chair: Dina Popovic, Spain

S-61-001
Genetic basis of suicidal behaviour
Alessandro Serretti, Italy

S-61-002
Mixed features and suicidality: Is DSM 5 wrong?
Dina Popovic, Spain
S-61-003
How does clinical prediction of suicidality affect our daily clinical practice?
Mark Weiser, Israel
M. Davidson

S-61-004
Suicidality and overlapping geographical maps: Spurious correlations or cues for an underlying biological substrate?
Konstantinos Fountoulakis, Greece

T49: SUICIDE: BASIC/CLINICAL

S-62
11:00–12:30
Innovative approaches in suicide research
Chair: Philippe Courtet, France
Co-Chair: Sidney Kennedy, Canada

S-62-001
Initiative for research network
Sidney Kennedy, Canada

S-62-002
Neurosciences based phenomenology of suicidal behaviour
Philippe Courtet, France

S-62-003
MeMind project: Ambulatory assessment in suicide behaviour. Do different things to expect different results?
Enrique Baca García, Spain

S-62-004
The use of machine learning and big data to predict suicide
Michael Berk, Australia

T33: PHARMACOLOGY

S-63
11:00–12:30
Atypical neurotransmitters in psychiatry: Relevance for future therapeutics
Chair: Gregers Wegener, Denmark
Co-Chair: Sâmia Joca, Brazil

S-63-001
Nitric oxide signalling in psychiatric disorders: Evidence from Gene x Environment x Development (GxExD) studies
Gregers Wegener, Denmark

S-63-002
ATP and NO interaction in stress models of depression
Sâmia Joca, Brazil

S-63-003
The endocannabinoid and endovanilloid system in stress-coping responses
Fabricio Moreira, Brazil

S-63-004
Neurotrophins and psychiatric disorders
Eero Castrén, Finland

T43: SCHIZOPHRENIA: BASIC/CLINICAL

S-64
11:00–12:30
Operationalizing the dysconnection syndrome: Translational approaches reveal brain network dysfunction in schizophrenia
Chair: Bernat Kocsis, USA
Co-Chair: Vaibhav Diwadkar, USA

S-64-001
Dysconnection in rodent models of schizophrenia: Directed connectivity analyses of frequency-tagged oscillatory coupling of frontal-hippocampal signals
Bernat Kocsis, USA

S-64-002
Ketamine disrupts the functional state of corticothalamic systems: A mechanistic model of first-episode psychosis
Didier Pinault, France

S-64-003
Structural and functional brain dysconnectivity predating the onset of psychosis
Stefan Borgwardt, Switzerland

S-64-004
The dynamics of the functional “dysconnectome” in schizophrenia: Network modeling of in vivo fMRI signals
Vaibhav Diwadkar, USA

T24: NEUROPATHOLOGY

S-65
11:00–12:30
Cell-type specific epigenetic, proteomic and gene expression signatures in schizophrenia: New findings from post-mortem investigations
Chair: Peter Falkai, Germany
Co-Chair: Andrea Schmitt, Germany

S-65-001
Alteration of genome-wide gene expression in hippocampal CA4 pyramidal neurons in schizophrenia
Andrea Schmitt, Germany
S-65-002
Is the energy dysfunction observed in schizophrenia brains being originated in oligodendrocytes?
Daniel Martins de Souza, Brazil

S-65-003
Integrated analysis of cell-type specific epigenome-wide methylation changes in schizophrenia brains
Theo Kraus, Germany
A. Schmitt, J. Spanner, P. Falkai, A. Giese

S-65-004
Epigenetic signatures in the brain of schizophrenia patients
Andre Fischer, Germany

T33: PHARMACOLOGY

S-66
11:00–12:30
NMDA receptor antagonists in psychiatry
Chair: Peter Gass, Germany
Co-Chair: Gerard Sanacora, USA

S-66-001
Glutamatergic mechanisms in schizophrenia: Focus on genetics
Dan Rujescu, Germany

S-66-002
Insight into Ketamine's effect via cross-species translational neuroimaging
Oliver Grimm, Switzerland

S-66-003
Molecular and cellular determinants of the pleiotropic effects of NMDA receptor antagonists
Dragos Inta, Germany

S-66-004
Antidepressant effects of NMDA receptor targeting drugs
Gerard Sanacora, USA

T11: DEPRESSION: BASIC/CLINICAL

S-67
11:00–12:30
Spectrum of Mood Disorders (MD): Where is the place for mixed states?
Chair: Trisha Suppes, USA

S-67-001
Mood Disorders (MD) and mixed states: Evolution in diagnostic classification
Roger McIntyre, Canada

S-67-002
Bipolar mixed states: Review of clinical presentation, treatment and outcomes
Mark Frye, USA

S-67-003
Major depressive disorder with mixed features: Epidemiology, clinical characteristics and prognosis
Allan Young, United Kingdom

S-67-004
Major depressive disorder with mixed features: Review of current treatment options
Trisha Suppes, USA

T25: NEUROIMAGING: GENETIC, FUNCTIONAL, STRUCTURAL

S-68
15:00–16:30
Dynamical brain: How brain complexity changes with aging and mental illness?
Chair: Chih-Chieh Yang, USA

S-68-001
Dynamical analysis of brain activity: A new research dimension
Chih-Chieh Yang, USA

S-68-002
Assessment of neurophysiological changes with electroconvulsive therapy in mental disorders using nonlinear approach
Ryoko Okazaki, Japan

S-68-003
Increasing signal variability during development and its relevance to autism spectrum disorders
Tetsuya Takahashi, Japan

S-68-004
Neurophysiological basis of creativity in healthy elderly people using nonlinear approach
Kanji Ueno, Japan
**T19: INFLAMMATION PSYCHIATRY**

**S-69**

15:00–16:30

**Increased intestinal permeability and bacterial translocation in neuro-psychiatric disorders**

*Chair:* Michael Maes, Australia  
*Co-Chair:* Yolanda Sanz, Spain

**S-69-001**

Increased intestinal permeability and bacterial translocation in depression and chronic fatigue syndrome  
*Michael Maes, Thailand*

**S-69-002**

Increased intestinal permeability and bacterial translocation in chronic stress animal models  
*Javier Caso, Spain*

**S-69-003**

Increased intestinal permeability and bacterial translocation in neurodevelopmental disorders  
*Yolanda Sanz, Spain*

**S-69-004**

Increased intestinal permeability and bacterial translocation in schizophrenia  
*Emily Severance, USA*

**T26: NEUROPHYSIOLOGY**

**S-70**

15:00–16:30

**Current use of EEG-based techniques in psychiatry**

*Chair:* Martijn Arns, The Netherlands  
*Co-Chair:* Adam Wichniak, Poland

**S-70-001**

Epilepsy spectrum disorders and episodic psychiatric symptoms  
*Nash N. Boutros, USA*

**S-70-002**

Results of the international multi-center iSPOT-A study in ADHD: EEG predictors of treatment outcome to methylphenidate  
*Martijn Arns, The Netherlands*

**S-70-003**

Did the No-Go P300 component help to predict relapse in recently detoxified alcoholic patients?  
*Salvatore Campanella, Belgium*

**S-70-004**

Polysomnographic measures of sleep in psychiatry: Implications for diagnosis and treatment  
*Adam Wichniak, Poland*

**T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC/CLINICAL**

**S-71**

15:00–16:30

**Sex-specific neuroendocrinological findings in conduct disorder**

*Chair:* Sabine Herpertz, Germany  
*Co-Chair:* Christine Freitag, Germany

**S-71-001**

The brain oxytocin system in intermale and female aggression in rodents  
*Trynke DeJong, Germany*  
*I. Neumann*

**S-71-002**

Sex-specific differences in oxytocin effects on the brain’s salience circuit  
*Ruth Schmitt, Germany*

**S-71-003**

Sex-specific differences and the effects of puberty on emotional processing in adolescents with and without conduct disorder  
*Kerstin Konrad, Germany*

**S-71-004**

The role of basal and reactive steroid hormones and neuropeptides in female conduct disorder  
*Christine Freitag, Germany*  
*A. Martinelli, K. Ackermann, A. Bernhard, FemNAT-CD study team*

**T6: BIPOLAR DISORDERS: BASIC/CLINICAL**

**S-72**

15:00–16:30

**Socio-demographic and clinical differences between Bipolar I and II Disorder (BP) and implications for treatment**

*Chair:* Carlo Altamura, Italy  
*Co-Chair:* Bernardo Dell’Osso, Italy

**S-72-001**

Bipolar I vs II Disorder (BP): Characterization of socio-demographic and clinical variables in Italian and American samples  
*Bernardo Dell’Osso, Italy*

**S-72-002**

Clinical implications of predominant polarity and polarity index in Bipolar Disorders (BP)  
*Eduard Vieta, Spain*
Preliminary Scientific Programme / Symposia, Workshops

Workshops

► Sunday, 18 June 2017

T51: NATIONAL INITIATIVES

<table>
<thead>
<tr>
<th>WS-01</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30–10:00</td>
</tr>
<tr>
<td>Initiatives from the Spanish Society of Biological Psychiatry: From evidence to experience</td>
</tr>
<tr>
<td>Chair: Miquel Bernardo, Spain</td>
</tr>
<tr>
<td>Co-Chair: Ana Gonzalez Pinto, Spain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WS-01-001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agitation consensus</td>
</tr>
<tr>
<td>Eduard Vieta, Spain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WS-01-002</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECT consensus</td>
</tr>
<tr>
<td>Mikel Urretavizcaya, Spain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WS-01-003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical guidelines for adult patients with a severe mental disorder and a comorbid substance use</td>
</tr>
<tr>
<td>Luis San, Spain</td>
</tr>
</tbody>
</table>

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC/CLINICAL

<table>
<thead>
<tr>
<th>WS-02</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15–11:45</td>
</tr>
<tr>
<td>New investigations on the relationship between working memory and ADHD</td>
</tr>
<tr>
<td>Chair: Joseph Biederman, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WS-02-001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical correlates of working memory deficits in youth with and without ADHD</td>
</tr>
<tr>
<td>Ronna Fried, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WS-02-002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Are working memory deficits and ADHD sissociable?: An IMRI study</td>
</tr>
<tr>
<td>Joseph Biederman, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WS-02-003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduced prefrontal efficiency for visuospatial working memory in attention-deficit/hyperactivity disorder</td>
</tr>
<tr>
<td>Jeffrey Newcorn, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WS-02-004</th>
</tr>
</thead>
<tbody>
<tr>
<td>Working memory deficits in a prenatal nicotine exposure mouse model</td>
</tr>
<tr>
<td>Pradeep Bhide, USA</td>
</tr>
</tbody>
</table>
### Monday, 19 June 2017

**T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)**

**WS-03**

11:15 – 12:45  
**Current status of electroconvulsive therapy in the treatment of major psychiatric disorders**  
*Chair: Yong-Sik Kim, Republic of Korea*  
*Co-Chair: Pascal Sienaert, Belgium*

**WS-03-001**  
**Current status on efficacy of ECT**  
*Hans Mørch Jensen, Denmark*

**WS-03-002**  
**Mechanism of ECT focused on psychosis**  
*Ung-Gu Kang, Republic of Korea*

**WS-03-003**  
**ECT for the treatment resistant psychosis**  
*In-Won Chung, Republic of Korea*

**WS-03-004**  
**ECT in catatonia**  
*Pascal Sienaert, Belgium*

### T11: DEPRESSION: BASIC/CLINICAL

**WS-04**

15:00 – 16:30  
**Rethinking depression in the Century XXI: Where are we now in biological psychiatry?**  
*Chair: Victoria Valdez, Argentina*  
*Co-Chair: Adriana Rivetti, Argentina*

**WS-04-001**  
**Is depression an inflammatory-metabolic disease?**  
*Andrea Marquez Lopez Mato, Argentina*

**WS-04-002**  
**Genetics risk variants for major depressive disorder**  
*Alejo Corrales, Argentina*

**WS-04-003**  
**Rethinking depression in the Century XXI**  
*Victoria Valdez, Argentina*

**WS-04-004**  
**Serotonergic hypothesis of depression: Is still up-to-date?**  
*Adriana Rivetti, Argentina*

### Tuesday, 20 June 2017

**T43: SCHIZOPHRENIA: BASIC/CLINICAL**

**WS-05**

08:30 – 10:00  
**Gesture as window to psychosis pathobiology: From aberrant body experience to social interaction**  
*Chair: Sebastian Walther, Switzerland*  
*Co-Chair: Vijay Mittal, USA*

**WS-05-001**  
**Schizophrenia in the flesh: Empirical studies of anomalous bodily self experiences**  
*So-Hee Park, USA*

**WS-05-002**  
**Impaired gesture performance in schizophrenia: Neurobiology and clinical consequences**  
*Sebastian Walther, Switzerland*

**WS-05-003**  
**The neural correlates of natural social-communicative perception processes in patients with schizophrenia: Understanding, recognition and interpretation of verbal and non-verbal information**  
*Benjamin Straube, Germany*

**WS-05-004**  
**What can gesture-speech mismatch tell us about pathophysiology underlying psychosis-risk syndromes?**  
*Vijay Mittal, USA*

**T49: SUICIDE: BASIC/CLINICAL**

**WS-06**

11:15 – 12:45  
**Neurobiology of suicidal behaviour**  
*Chair: Leo Sher, USA*  
*Co-Chair: Zoltan Rihmer, Hungary*

**WS-06-001**  
**Testosterone and suicidal behavior in men and women**  
*Leo Sher, USA*

**WS-06-002**  
**Suicide in men: Clinical and biological correlates**  
*Zoltan Rihmer, Hungary*

**WS-06-003**  
**Neuroinflammatory biomarkers of suicidal behavior**  
*Jussi Jokinen, Sweden*

**WS-06-004**  
**Endophenotypes of suicidal behavior for genetic research**  
*Xenia Gonda, Hungary*
WS-07
15:00–16:30
Merging evidence and clinical practice in management of depression: The CANMAT experience
Chair: Sidney Kennedy, Canada
Co-Chair: Roumen Milev, Canada

WS-07-001
Guidelines for Pharmacological Management of Depression
Raymond Lam, Canada

WS-07-002
Making Effective Guidelines: Examples of Evidence-based Dissemination and Implementation Strategies
Sagar Parikh, USA

WS-07-003
Guidelines for the treatment of depression in specific populations: making decisions despite gaps in evidence
Glenda MacQueen, Canada

WS-07-004
Guidelines for the use of complementary and alternative medicines (CAM) in major depression
Arun Ravindran, Canada

WS-08
15:00–16:30
Functional neuroanatomy of hallucinations
Chair: Rajesh Nagpal, India
Co-Chair: Harishchandra Gambheera, Sri Lanka

WS-08-001
Functional neuroanatomy of auditory hallucinations
E. Mohandas Warrier, India

WS-08-002
Neural signature of visual hallucinations
Venu Gopal Jhanwar, India

WS-08-003
Neural mechanisms of somatic, musical and extracampine hallucinations
Anukant Mital, India

WS-08-004
The neural signature overlap between delusions and hallucinations
Debashis Ray, India

WS-09
11:15–12:45
Schizophrenia research in Chile
Chair: Hernan Silva, Chile
Co-Chair: Veronica Larach, Chile

WS-09-001
BDNF as a biomarker of cognitive function in schizophrenia: A study in Chilean population
Hernan Silva, Chile

WS-09-002
Pragmatic and linguistic disorders in schizophrenia since the first episode
Eduardo Duran, Chile

WS-09-003
Atypical antipsychotics and psychosis spectrum: Chilean experience
Eugenio Olea, Chile

WS-09-004
Universal coverage for schizophrenia: The GES programme in Chile
Veronica Larach, Chile

WS-10
15:00–16:30
Evidence for brain stimulation methods in schizophrenia
Chair: Joachim Cordes, Germany
Co-Chair: Christian Plewnia, Germany

WS-10-001
Effects of transcranial direct current stimulation (tDCS) on executive functions
Christian Plewnia, Germany

WS-10-002
rTMS for the treatment of negative symptoms in residual schizophrenia
Joachim Cordes, Germany

WS-10-003
The treatment of hallucinations in schizophrenia spectrum disorders
Iris Sommer, The Netherlands

WS-10-004
Predictors of response to ECT in treatment-resistant schizophrenia
Tomasz Pawelczyk, Poland
The scientific programme of the WFSBP 2017 Congress will cover the following topics. Within each topic the track may be basic, clinical, interface or conceptual:

1. Addictive Disorders
2. Antidepressants: Basic/Clinical
3. Antipsychotics: Basic/Clinical
4. Anxiety Disorders: Basic/Clinical
5. Anxiolytics: Basic/Clinical
6. Bipolar Disorders: Basic/Clinical
7. Childhood & Adolescent Disorders: Basic/Clinical
8. Chronobiology and Psychiatry
9. Cognitive Neuroscience
10. Dementia: Basic/Clinical
11. Depression: Basic/Clinical
12. Eating Disorders: Basic/Clinical
13. Emergency Psychiatry
14. Epidemiology
15. Ethics in Biological Psychiatry
16. Forensic Psychiatry
17. Genetics
18. Hypnotics: Basic/Clinical
19. Inflammation Psychiatry
20. Liaison Psychiatry
21. Mental Retardation or Chromosomal Aberrations: Basic/Clinical
22. Molecular Neurobiology
23. Mood Stabilisers: Basic/Clinical
24. Neuropathology
25. Neuroimaging: Genetic, Functional, Structural
26. Neurophysiology
27. Obsessive-Compulsive Disorders: Basic/Clinical
28. Pain: Basic/Clinical
29. Panic Disorders: Basic/Clinical
30. Personality Disorders: Basic/Clinical
31. Pharmacoeconomics
32. Pharmacogenetics
33. Pharmacology
34. Phototherapy
35. Posttraumatic Stress: Basic/Clinical
36. Pregnancy, post partum and new born: Basic/Clinical
37. Premenstrual Syndrome: Basic/Clinical
38. Psychogeriatrics
39. Psychoneuroimmunology
40. Psychopathology
41. Psychosurgery
42. Psycho-Oncology
43. Schizophrenia: Basic/Clinical
44. Sexual Disorders: Basic/Clinical
45. Sleep Disorders: Basic/Clinical
46. Somatoform Disorders: Basic/Clinical
47. Stimulation Methods (ECT, TMS, VNS, DBS)
48. Stress: Basic/Clinical
49. Suicide: Basic/Clinical
50. Violence: Basic/Clinical
51. Miscellaneous
Call for Abstracts for Free Communications and Posters

Deadline for abstract submission: 6 December 2016
Notification of acceptance/rejection: Early March 2017

Authors of Free Communications or Posters are hereby kindly invited to submit an abstract for contributions to the WFSBP 2017 Congress by using the online submission form on the congress website www.wfsbp-congress.org. Please note that online submission is mandatory.

Free Communications and Posters submitted individually and accepted by the International Scientific Programme Committee will be grouped by category topics into thematic sessions in order to promote communication among the presenters and participants and to allow for inspiring discussions.

FREE COMMUNICATIONS
Free Communications will be selected by the International Scientific Programme Committee after abstract submissions have been reviewed. The 90-minute sessions will be grouped by topics and chaired by selected specialists. The time slot for a single presentation in a Free Communication session is 15 minutes including discussion time. Only 1 Free Communication abstract may be submitted per author.

POSTERS
Each accepted poster will be exhibited at the WFSBP 2017 Copenhagen Congress at the Bella Center. The best posters will be grouped into thematic Guided Poster Tours chaired by renowned specialists. The Guided Poster Tours will give authors the opportunity to present their findings and discuss them with the audience. A maximum of 4 posters abstracts may be submitted per author. The congress will deliver WFSBP Young Investigator Awards for the five best posters. Please refer to page 43 for further information.

GUIDELINES FOR THE PREPARATION OF ABSTRACTS
Please submit your abstracts online and in English, the official language of the WFSBP Congress 2017.

► Please choose a title that clearly indicates the content of the contribution.
► Please avoid abbreviations in the title. Abbreviations may be used in the text if they are defined when used first.
► The author’s name (full first name, family name) and place of work (institution, city, country) should be given. Degrees, titles, street addresses, and acknowledgments of support should be omitted, however.
► The abstract submission must be complete.
► Please choose a topic from the topic list.
► The text of the abstract should briefly state: Objectives (indicate the purpose of the study or the hypothesis that was tested), Methods (include the setting for the study, the subjects, the diagnosis or intervention, and the type of statistical analysis. If references are needed, they should be given in the text), Results (present as clearly as possible the outcome of the study and statistical significance if appropriate) and Conclusions (briefly discuss the data and emphasize the significance of the results). References need to be given in the text.
► The length of your abstract is limited to a maximum of 300 words.
► Please ensure that the abstract does not contain spelling, grammar or scientific errors, as it will be reproduced exactly as submitted. Submitted abstracts will not be edited in any way. If the abstract does not fulfill the necessary requirements it cannot be published.
► A disclosure of the existence of any significant financial interest or other affiliations with a funding organisation or with a commercial supporter of the session and/or provider of commercial services is required.
► All abstracts will be published online in the scientific programme of the WFSBP Congress from April 2017.
► Only 1 Free Communication Abstract/Young Scientist Award Abstract may be submitted per author.
► A maximum of 4 posters may be submitted by each author.

Please note that accepted abstracts will be published only after completed registration and payment of the congress registration fee. The acceptance of submitted abstracts simultaneously results in binding registration of the speaker to attend the conference. The registration fee must be paid immediately after receiving the abstract acceptance, at the latest until 20 March 2017. Authors who have not settled the registration fee until that date will be omitted from the scientific programme. Onsite registration for presenting authors is not possible.
Submission Procedure
Abstracts for Free Communications, Young Scientist Awards and Posters have to be submitted electronically by using the online form on the congress website www.wfsbp-congress.org.
Detailed instructions regarding the electronic submission procedure can be found on the website.

For any further assistance, please contact the congress and exhibition office:

CPO HANSER SERVICE
Phone: +49 – 30 – 300 669-0
Email: wfsbp2017@cpo-hanser.de

We organize your success
CPO HANSER SERVICE is specialized in the field of Conference, Event, Destination Management and, association Management and has been organizing events of any size throughout Germany and worldwide for more than 35 years.

We offer you:
- the best congress organization
- state-of-the-art online solutions
- electronic abstract handling
- CME accreditation handling
- effective congress technology
- sponsoring and exhibition acquisition and management
- finance management
- professional tax solutions
- creative event programs
- inhouse graphic design

www.cpo-hanser.de
Format Descriptions of the Scientific Sessions

OPENING LECTURE
The Opening Lecture will be held during the Opening Ceremony on 18 June 2017.

PLENARY LECTURES
Plenary Lectures are 45-minute sessions held by renowned experts. The speakers have been chosen among the most prominent researchers in the respective field.

DEBATES
Debates are intended to offer a platform for a lively, yet balanced discussion on controversial issues. A moderator (chairperson) and two speakers (one proponent and one opponent) will state their opinions on different subjects.

WFSBP TASK FORCE SYMPOSIA
A good number of WSFBP Task Forces have submitted Symposia organised by their key members on issues related to their field of special expertise. All of them have been included in the scientific programme and pertain to Treatment Guidelines, Consensus Statements and other hot topics in their respective thematic areas.

WFSBP TASK FORCE WORKSHOPS
A good number of WSFBP Task Forces have submitted Workshops organised by their key members on issues related to their field of special expertise. All of them have been included in the scientific programme and pertain to Treatment Guidelines, Consensus Statements and other hot topics in their respective thematic areas.

SYMPOSIA
Symposia are selected, covering basic, clinical, interface, and conceptual topics of Biological Psychiatry. Symposia are 90-minute sessions and will be organised and chaired by the experts whose proposals are accepted by the International Scientific Programme Committee.

WORKSHOPS
Workshops are 90-minute highly interactive sessions with an educational focus. This format is designed to give specific regions a platform for presentation and networking.

FREE COMMUNICATIONS
Authors are invited to submit abstracts on their latest research findings. All submitted abstracts will be reviewed and the best will be selected and allocated to Free Communication Sessions.

GUIDED POSTER TOURS
Abstracts on new research findings and/or major research efforts are expected to be submitted for the poster category. For those abstracts which will be submitted by young investigators for the poster category, the Local Organising Committee will arrange Guided Poster Tours to give the authors the opportunity to present these findings and discuss them with the audience.

EDUCATIONAL GRANT SESSIONS
(Young Scientists Award Sessions)
These sessions are dedicated to young researchers up to 40 years of age which will be pre-selected via an application process. Herewith the WFSBP is promoting education for talented young researchers. Interactional and practical learning is in the focus of these sessions. The educational grant sessions are open to all congress delegates.

INDUSTRY SPONSORED SYMPOSIA
These 60- to 90-minute sessions are fully integrated into the congress. The sessions are organised and executed by the pharmaceutical industry by unrestricted educational grants.

CME ACCREDITATION
An application will be made to the EACCME® for CME accreditation of this event.
The following WFSBP Awards will be delivered and presented during the 13th World Congress of Biological Psychiatry 2017 in Copenhagen.

**WFSBP Lifetime Achievement Award in Biological Psychiatry**
The WFSBP Lifetime Achievement Award in Biological Psychiatry is intended for senior research scientists (MD, PhD or equivalent) whose lifework has significantly influenced today’s field of biological psychiatry. This award is open to members and non-members of the WFSBP. It consists of a monetary award of EUR 1,000.

**WFSBP Award for Scientific Excellence of the WFSBP Host**
The WFSBP Award for Scientific Excellence of the WFSBP Host is dedicated to an outstanding researcher in the field of Biological Psychiatry originating from the host country of the World Congress of Biological Psychiatry. This award consists of a monetary award of EUR 1,000.

**WFSBP Research Prize**
The WFSBP Research Prize is intended for WFSBP members (MD, PhD or equivalent) whose current scientific work has had an important impact in the field of clinical and/or basic research in the area of biological psychiatry. This prize consists of a monetary award of EUR 1,000.

**WFSBP Award for Excellence in Education**
The WFSBP Award for Excellence in Education is to acknowledge outstanding and innovative education in biological psychiatry including the implementation of new interactive media. The WFSBP Education prize is open to all WFSBP members who have improved the education in all fields of Psychiatry. This award consists of a monetary award of EUR 1,000.

**WFSBP Young Investigator Awards for the five best posters (under 40 year-old)**
An application for the Young Investigator Award is not necessary. All posters will be evaluated at the congress. The awards will go to those presentations that not only provide evidence of innovative research, but which are also well presented.

Please note that presenting authors must register and attend the meeting to be eligible for any of these awards.

Applications must be sent by e-mail to the congress and exhibition office:

**CPO Service**
Phone: +49 – 30 – 300 669-0
Email: wfsbp2017@cpo-hanser.de

by 6 December 2016 and should include a short summary of the work and a brief CV. The letter should outline the main professional activities and provide key peer review publications. Prizes will be announced during the Opening Ceremony. Poster prizes will be delivered during the Closing Ceremony.
Congress Information

Congress Registration for the 13th World Congress of Biological Psychiatry is available via the congress website at www.wfsbp-congress.org.

<table>
<thead>
<tr>
<th>Registration and payment received</th>
<th>Early registration by 25 January 2017 EUR</th>
<th>Late registration by 31 May 2017 EUR</th>
<th>On-site registration after 31 May 2017 EUR</th>
</tr>
</thead>
<tbody>
<tr>
<td>WFSBP Members</td>
<td>530</td>
<td>630</td>
<td>730</td>
</tr>
<tr>
<td>Non-Members</td>
<td>630</td>
<td>730</td>
<td>830</td>
</tr>
<tr>
<td>Participants from Low-Income Countries*</td>
<td>290</td>
<td>390</td>
<td>490</td>
</tr>
<tr>
<td>Trainees**</td>
<td>290</td>
<td>390</td>
<td>490</td>
</tr>
</tbody>
</table>

* According to the Low-Income-Countries defined by the world bank. Please see the list on the WFSBP website www.wfsbp-congress.org

** Trainee/Student status must be confirmed by certificate in writing by head of department and is applicable only for participants born after 1 Jan 1982. Please send your certificate by email or fax to: CPO HANSER SERVICE GmbH, Fax: +49 – 30 – 305 73 91, Email: wfsbp2017@cpo-hanser.de

PAYMENT
When registering for the WFSBP 2017 Congress in Copenhagen, please arrange for payment of the registration fee. All payments should be made in EURO. You may choose between two modes of payment: **credit card payment** or **bank transfer**. Especially for payment made from outside Germany where the congress office is based, we strongly recommend credit card payments as charges for bank transfers may apply twice, once in the country of origin and a second time in Germany.

Please choose one mode of payment:
Credit card: AMEX, Mastercard or VISA
or bank transfer to the congress bank account:
CPO HANSER SERVICE w/WFSBP ZB 2017
Deutsche Bank Privat- u. Geschäftskunden AG, Berlin/
Bank Code: 1007 0024
Account Number: 108 96 97 02
BIC: DEUT DE DB BER
IBAN: DE 45 1007 0024 0108 9697 02

CONFIRMATION
Upon receipt of the registration and the corresponding payment, the congress office will send a confirmation form which also serves as an invoice. Please show this confirmation of registration at the congress counter when picking up your congress materials.

CANCELLATION OF CONGRESS PARTICIPATION
Notice of cancellation should be sent in writing only to the Congress Office CPO HANSER SERVICE. In case of cancellation by 25 January 2017 the payment will be refunded, minus a handling charge of 25%. No refund will be made after 25 January 2017.

ON-SITE REGISTRATION AFTER 31 MAY 2017
On-site registration will be possible but we recommend to register well in advance. Participants who wish to register on-site are advised to arrive early. On-site registration does not entitle participants to receive a delegate bag. On-site registration will be handled on a first-come, first-served basis, priority will be given to pre-registered delegates.
CONGRESS VENUE
Bella Center Copenhagen
Center Boulevard 5
2300 Copenhagen S, Denmark
Entrance: Congress Foyer

CONGRESS REGISTRATION DESK
The congress counter will be located in the Foyer.

<table>
<thead>
<tr>
<th>Preliminary opening hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 17 June 2017</td>
</tr>
<tr>
<td>Sunday, 18 June 2017</td>
</tr>
<tr>
<td>Monday, 19 June 2017</td>
</tr>
<tr>
<td>Tuesday, 20 June 2017</td>
</tr>
<tr>
<td>Wednesday, 21 June 2017</td>
</tr>
<tr>
<td>Thursday, 22 June 2017</td>
</tr>
<tr>
<td>16:00–19:00</td>
</tr>
<tr>
<td>07:30–19:00</td>
</tr>
<tr>
<td>08:00–18:30</td>
</tr>
<tr>
<td>08:00–18:30</td>
</tr>
<tr>
<td>08:00–18:30</td>
</tr>
<tr>
<td>08:00–17:30</td>
</tr>
</tbody>
</table>

CONGRESS AND EXHIBITION OFFICE
CPO HANSER SERVICE
Phone: +49 – 30 – 300 669-0
Email: wfsbp2017@cpo-hanser.de

POSTER EXHIBITION
Posters will be displayed from Monday, 19 June to Thursday, 22 June 2017 in Hall A 1 next to the technical exhibition. Each congress day there will be one Guided Poster Tour with the best posters only. The posters selected for the Guided Poster Tour will be displayed in a special area of the congress center. During the review of the abstracts which is done by the Local Organising Committee, the reviewers will indicate the candidates for the Guided Poster Tours. All other posters will be displayed for one entire congress day and grouped according to topics.

Information regarding poster format, set-up and dismantling will be sent to the authors along with their notification of acceptance.

TECHNICAL EXHIBITION
The WFSBP Congress 2017 will be accompanied by a major technical exhibition taking place in Hall A 1 of the Bella Center. Potential exhibitors can request an exhibition/sponsoring brochure from the exhibition office CPO HANSER SERVICE.
Email: wfsbp2017@cpo-hanser.de

<table>
<thead>
<tr>
<th>Preliminary opening hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, 19 June 2017</td>
</tr>
<tr>
<td>Tuesday, 20 June 2017</td>
</tr>
<tr>
<td>Wednesday, 21 June 2017</td>
</tr>
<tr>
<td>09:00–17:00</td>
</tr>
<tr>
<td>09:00–17:00</td>
</tr>
<tr>
<td>09:00–17:00</td>
</tr>
</tbody>
</table>

CONGRESS INFORMATION SYSTEM /
CO CONGRESS ONLINE®
The web based Congress Information System CO CONGRESS ONLINE® has been installed at www.wfsbp-congress.org

Prior to the congress, CO CONGRESS ONLINE® will provide information on:
► Preparation of the congress
► List of topics
► Call for abstracts
► Invited speakers and invited conveners of symposia
► Preliminary scientific programme
► Accepted abstracts
► List of exhibitors
► Information about the main sponsors
► Copenhagen
► Hotel accommodation
► Travel to Copenhagen
► Special news
► Private mailbox

In due time, the final programme will be published on CO CONGRESS ONLINE® which enables each participant to create her/his personal congress programme schedule. CO CONGRESS ONLINE® offers an extensive congress service.
General Information

**FINAL PROGRAMME**
The final programme and abstracts will be published on the Internet at [www.wfsbp-congress.org](http://www.wfsbp-congress.org) prior to the congress.

**WFSBP 2017 CONGRESS APP MOBILE**
The WFSBP 2017 Congress App is free for congress participants and provides iPhone/iPad and android smartphone users at WFSBP 2017 in Copenhagen with on-the-go access to the congress. The most up-to-date congress schedule is available at the fingertips during the congress.

**CONGRESS LANGUAGE**
The official language of the WFSBP Congress 2017 is English. Simultaneous translation will not be provided.

**LETTER OF INVITATION**
The congress will be pleased to send a formal letter of invitation to any registered delegate requesting one. It is understood that such an invitation is intended to help potential delegates to raise funds or to obtain a visa. This does not imply a commitment from the congress to provide any financial support. Letters of invitation may be requested from the congress office.

**VISA**
The entry formalities for Denmark vary according to the country of origin. The Ministry of Foreign Affairs of Denmark provides a list of countries that require a visa to enter the country. Please visit the website [http://um.dk/en](http://um.dk/en).

**OFFICIAL ITALIAN AGENCY**
For Italian delegates only:
Any Italian pharmaceutical company supporting or participating in a congress abroad, is subjected to an authorization by AIFA (Italian Drug Agency), according to an Italian Government Decree (Decreto Legislativo 219/06 – art. 124). The request of authorization must be submitted within 60 days before the starting date of the event. The appointed agency to collect all applications from pharmaceutical companies and file them with the AIFA is:

AIM Group International – AIM Education S.r.l.
Valentina Disabato/Cristina Ghidoli
Via G. Ripamonti, 129 | 20141 Milan, Italy
Phone: +39–02–56601.288/360
Fax: +39–02–70048585
Email: aifa@aimgroup.eu
www.aimgroupinternational.com

**INSURANCE**
Please note that the congress fee does not include insurance. All participants should arrange for their own insurance. Health and accident insurance is strongly recommended and will need to be purchased in the country of origin.

**FORCE MAJEURE**
For reasons beyond its control (such as war, strikes, lockouts, riots or any such civil disturbances, any natural disaster, including but not limited to earthquakes, floods, droughts and typhoons and any other cause of circumstance of whatsoever nature beyond control) that have an impact on the arrangements, timetables or planning of the 13th World Congress of Biological Psychiatry (WFSBP 2017) and its corresponding activities in Copenhagen, WFSBP has the right to immediately alter or cancel the activities or events or any of the arrangements, timetables, plans or other items relating directly or indirectly thereto. No party involved shall be entitled to any compensation for damages that result from such alteration or cancellation.

**CURRENCY**
The Danish currency is the Danish Krone (DKK). The Danish Krone is pegged to the Euro and convertible on world currency markets. The exchange rate fluctuates daily depending on the money market.

[www.oanda.com](http://www.oanda.com)

**CLIMATE**
Copenhagen is in the oceanic climate zone. Summer months are moderately warm and quite pleasant. June is the sunniest month of the year with an average of about eight hours of sunshine a day and the temperature varies between 11°C (52 °F) and 19°C (66°F).

**TRAVEL TO COPENHAGEN AND BELLA CENTER**
By plane Copenhagen is easy accessible from many European airports with direct flight connections. It is the largest airport in Scandinavia. From Copenhagen Airport it takes 10 minutes to reach the Bella Center. A regional train runs from the airport to Ørestad Station, the train station of the Bella Center.

By train Copenhagen Central Station is located in the heart of the city, bordering to the rough but also trendy Vesterbro. It is a gateway to all public transportation in and out and around Copenhagen. From Copenhagen Central Station it takes approx. 10 minutes by metro to reach the Bella Center. The name of the metro station is also Bella Center.
By car Bella Center is located at Center Boulevard 5, 2300 Copenhagen S. Follow the „Airport Motorway“, E20. The exit to Center Boulevard is number 19 and is called „Ørestad“ with „Bella Center“ listed below.

PUBLIC TRANSPORTATION IN COPENHAGEN
Public transportation in Copenhagen is reliable, punctual, and it goes everywhere in the city. In Copenhagen the trains, metro and busses (including waterbuses) can be accessed with the same ticket. All you need to know is how many zones you will pass on your journey. Note the metro will take you from the airport to central Copenhagen in only 13 minutes.

TAXIS TO BELLA CENTER
Bella Center is just a 10 – 15 minute taxi drive from Copenhagen Central Station and not more than 10 minutes from Copenhagen Airport by taxi. A taxi from Bella Center to the city centre costs about DKK 200-250. A taxi from Bella Center to Copenhagen Airport costs about DKK 150-200.

CITY OF COPENHAGEN
Copenhagen is not only the capital of Denmark. It is a cultural and economic center of Northern Europe. More than 1,2 million citizens live in the greater Copenhagen region.

The city is located on the Danish Island „Sæland“ (Danish: Sjælland) and next to the „Oresund“ – a Baltic sea seagate and natural borderline to Sweden. Due to this geographic location, Copenhagen – together with the Swedish city Malmö – represents the binational „Oresund Region“. It is a unique metropolis area, where two countries and cities are connected via the 8 km „Oresund Bridge“.

The Copenhagen Palaces Christiansborg and Amalienborg are the seat of the Danish Parliament and the residence of the Danish Queen Margrethe II. Architecture, design and music make Copenhagen an outstanding cultural hotspot in Northern Europe. It is famous for its innovative improvements which can be seen and experienced throughout the city.

Also, Copenhagen has great museums to offer, for example Louisiana and The National Gallery of Denmark. The Royal Danish Opera, located directly at the harbor front, is combining modern Danish architecture with international performances. The main sightseeing spots and touristic attractions are the Tivoli Gardens, Christiansborg, and of course the „Little Mermaid“ – the famos sculpture of Edvard Eriksen at the waterside.

The University of Copenhagen is offering a wide range of academic disciplines. With over 40,000 students and more than 9,000 employees, the University of Copenhagen is one of the largest institutions of research and education in the Nordic countries.

Due to short distances within the city of Copenhagen, its good public transportation system, and especially the well developed cycle paths, Copenhagen is a convenient place for meetings.
<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 December 2016</td>
<td>Deadline for abstract submission for free communications and posters</td>
</tr>
<tr>
<td>25 January 2017</td>
<td>Deadline early bird registration</td>
</tr>
<tr>
<td>31 May 2017</td>
<td>Deadline late registration</td>
</tr>
<tr>
<td>18 June 20157</td>
<td>Opening Ceremony and Networking Reception</td>
</tr>
</tbody>
</table>

www.wfsbp-congress.org